

AD \_\_\_\_\_

Award Number: DAMD17-00-1-0089

TITLE: Interferon Gamma and PSA-Restricted Expression of FAS  
Ligand: A Novel Gene Therapy Strategy for Prostate  
Cancer

PRINCIPAL INVESTIGATOR: Simon J. Hall, M.D.

CONTRACTING ORGANIZATION: Mount Sinai School of Medicine  
New York, New York 10029

REPORT DATE: March 2002

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are  
those of the author(s) and should not be construed as an official  
Department of the Army position, policy or decision unless so  
designated by other documentation.

20021025 321

# REPORT DOCUMENTATION PAGE

*Form Approved  
OMB No. 074-0188*

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE March 2002	3. REPORT TYPE AND DATES COVERED Annual (1 Mar 01 - 28 Feb 02)	
4. TITLE AND SUBTITLE Interferon Gamma and PSA-Restricted Expression of FAS Ligand: A Novel Gene Therapy Strategy for Prostate Cancer		5. FUNDING NUMBERS DAMD17-00-1-0089	
6. AUTHOR(S) Simon J. Hall, M.D.			
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)  Mount Sinai School of Medicine New York, New York 10029  E-Mail: halls01@doc.mssm.edu		8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)  U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES			
12a. DISTRIBUTION / AVAILABILITY STATEMENT  Approved for Public Release; Distribution Unlimited		12b. DISTRIBUTION CODE	
13. ABSTRACT ( <i>Maximum 200 Words</i> )  <p><u>Introduction:</u> Preliminary studies and work during the past 2 years illustrated the ability of IFN-<math>\gamma</math> to restore or enhance sensitivity to Fas transactivation <i>in vitro</i>. However, the combination of Ad.FasL and Ad.mIL-12 resulted in a worse survival than for Ad.IL-12 alone. Studies focused first on injection schemes to improve on these results and understand the mechanisms underlying the reversal of resistance to Fas transactivation by IFN-<math>\gamma</math>. Secondly, studies addressed the block in the Fas-apoptotic pathway mediated by IFN-<math>\gamma</math>.</p> <p><u>Results:</u> Based on the serum peaks of IL-12 (Days 2/8) and IFN-<math>\gamma</math> (4/11) measured following IL-12 gene therapy, a staggered injection pattern was developed, injecting orthotopic tumors with Ad.mIL-12 on day 6 and Ad.FasL on days 8 and 11. This resulted in a near tripling of apoptosis in combination treated tumors and a doubling of mean survival. In the human prostate cancer cell lines, PC3 and LNCaP, studies with caspase substrates noted that the CPP32 family was activated and not the ICE family following exposure to IFN-<math>\gamma</math> and sFasL. Cell death could be blocked by the general caspase inhibitor z-VAD-FMK and the CPP32 inhibitor, z-DEVD-FMK and not the ICE inhibitor, ac-YVAD-CMK.</p> <p><u>Conclusions:</u> These studies validate the concept of exploiting Fas upregulation for FasL transactivation using a sequential injection scheme of Ad.mIL-12 and Ad.FasL. Thus far, in the Fas sensitive cell line, PC3, and resistant cell line, LNCaP, sFasL activates the CPP32 family of caspases to induce apoptosis following IFN-<math>\gamma</math> treatment.</p>			
14. SUBJECT TERMS prostate cancer, cancer therapy, gene therapy, adenovirus, tissue specific gene expression, FAS, FAS ligand, gene expression		15. NUMBER OF PAGES 52	
		16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited

## **Table of Contents**

<b>Cover .....</b>	
<b>SF 298 .....</b>	
<b>Table of Contents .....</b>	
<b>Introduction .....</b>	<b>1</b>
<b>Body .....</b>	<b>1</b>
<b>Key Research Accomplishments .....</b>	<b>3</b>
<b>Reportable Outcomes .....</b>	<b>3</b>
<b>Conclusions .....</b>	<b>3</b>
<b>References .....</b>	
<b>Appendices .....</b>	<b>4</b>

## Introduction

Fas is a potential target expressed on the cell surface of many tumor cells. The binding of its ligand, FasL, initiates an intracellular cascade resulting in apoptosis.<sup>1</sup> This pathway was first identified within the lymphoid system where it is thought to act within the homeostatic mechanisms of T cells and other effectors. It is unknown why many tumors, including prostate, express Fas, but its use as a potential therapeutic target has generated interest. Immunohistochemical studies have shown that human prostate cancers express Fas. Established human prostate cancer cell lines have also been found to express Fas. Though many are generally resistant to agonist antibody Fas transactivation. Preliminary work for the grant and as reported in last year's report we found that pre-incubation of mouse and human prostate cancer cell lines could restore or enhance sensitivity to Fas transactivation. To further explore the potential of exploiting this phenomenon *in vivo* an adenovirus expressing FasL (Ad.FasL) was constructed and tested *in vitro* and *in vivo*. Combination studies were also performed, using an adenovirus expressing IL-12 (Ad.mIL-12) to drive the production of IFN- $\gamma$ . The underlying concept is to exploit Ad.mIL-12 to stimulate host production of IFN- $\gamma$  to up-regulate Fas, in addition to its ability to induce both innate and acquired immunity, and add Ad.FasL to target resulting Fas+ tumor cells.

## Body

### 1) Effect of IFN- $\gamma$ on the human cell lines PC3 and LNCaP.

Studies were performed demonstrating the ability of IFN- $\gamma$  to influence Fas transactivation via 2 methods. The first involved using an agonist anti-Fas antibody and the counting of viable cells. The second explored the use of soluble FasL to lyse cells with or without IFN- $\gamma$ . The methods are described on pages 5-6 and the results in Figure 1 in the attached manuscript. In both assays IFN- $\gamma$  either enhanced Fas sensitivity (PC3) or reversed Fas resistance (LNCaP).

### 2) In Vitro Activity of Ad.FasL

Studies explored the ability of AdFasL to inhibit the growth of the mouse prostate cancer cell line, RM-1 alone or in combination with 2 doses of IFN- $\gamma$ . The results are shown in Figure of the attached manuscript. Alone, Ad.FasL had limited effect of killing to 30-40%, which correlated to baseline Fas expression. The combination of Ad.FasL with IFN $\gamma$  induced higher levels of maximum cell kill, consistent with the resulting higher levels of Fas expression. More importantly the presence of IFN- $\gamma$  resulted in very high levels of cell

kill at very low doses of vector, indicating the presence of a bystander effect as hypothesized.

### 3) In Vivo Gene Therapy

Initial studies reported last year and in Figures 3 and 4 noted that in the short-term combination therapy resulted in smaller tumors, but in survival studies actually worsened survival compared to Ad.mIL-12 alone. We reasoned that perhaps combination therapy was inferior to due to the killing of Ad.mIL-12 transduced cells, thereby reducing both IL-12 and IFN- $\gamma$  levels. This in turn may reduce the other abilities of IL-12 in this model, induction of cytotoxic neutrophils, T cells, and NK cells, and the upregulation of Fas through a reduction of IFN- $\gamma$ . To test this hypothesis we injected Ad.mIL-12 into the contralateral lobe of the prostate which did not harbor a tumor with the injection of the tumor by Ad.FasL as before. In this assay as would be predicted injection of the contralateral lobe reduced the survival enhancing abilities of cytokine therapy, but when combined with intratumoral injection with Ad.FasL resulted in significantly enhanced tumor growth suppression (Figure 4B). We then staggered the injections of Ad.mIL-12 and Ad.FasL, as outlined on page 11 of the paper. This resulted in significant enhancement in survival (Figure 4C) and in apoptotic activity (Figure 5).

### 4) Caspase Activation in PC3 and LNCaP Cells

Studies then addressed the caspase cascade following Fas transactivation as outlined in Specific Aim 2. The initial study focused on discriminating the caspase family activated by FasL in these, focusing on the ICE family (caspases 1, 4,& 5), the CPP32 family (caspases 3,6,7,8,9, and 10) and the ICH/Nedd2 subfamily (caspase 2) using specific fluorescent substrates. In both LNCaP and PC3 cells we found high amounts of DEVDase indicative of the CPP32 family following FasL exposure. In the FasL sensitive cell line PC3 the addition of IFN- $\gamma$  increased levels of substrate indicating that cytokine pre-incubation enhanced the same pathway and did not re-route to another caspase pathway. To verify these results specific caspase inhibitors of each subfamily were used in the face of FasL. These studies noted that the CPP32 inhibitor, z-DEVD-FMK and not the ICE inhibitor, Ac-YVAD-CMK, blocked FasL-mediated cell lysis in both cell lines. Initial time course studies following Fas transactivation indicate that caspase 8 is the first caspase to be activated.

### 5) Related Fas/FasL Work

The preliminary work for the grant had noted the ability of Ad.mIL-12-IFN- $\gamma$  to influence the Fas/FasL pathway in the mouse prostate cancer model. This work was published last year in Human Gene Therapy and is attached. Furthermore, with partial support from this grant, parallel studies with Ad.mIL-12 and AdHSV-tk (Herpes Virus Simplex thymidine kinase) noted the importance of each of these therapies to independently influence Fas and FasL expression, respectively, to mediate a bystander effect. This work was published this year in Gene Therapy and is attached.

## Key Research Accomplishments

1. Enhancement of apoptosis and animal survival in an aggressive model of prostate cancer by staggered injections of Ad.mIL-12 and Ad.FasL.
2. Demonstration in human prostate cancer cells that the CPP32 family mediates Fas-mediated cell death

## REPORTABLE OUTCOMES

1. Selleck WA, Canfield SE, Hassen WA, Kuzmin AI, Eisensmith RC, Chen S-H, and Hall SJ. IFN- $\gamma$  Sensitization of Prostate Cancer Cells to Fas-Mediated Death: A Gene Therapy Approach. Submitted Mol Ther, 5/02.
2. Sanford MA, Yan Y, Canfield SE, Hassen W, Atkinson G, Chen SH, and Hall SJ. Independent Contributions of Gr-1+ Leukocytes and Fas/FasL Interactions to Induce Apoptosis Following IL-12 Gene Therapy in a Mouse Model of Prostate Cancer. Hum Gene Ther 12: 1485-1498, 2001.
3. Hall SJ, Canfield SE, Yan Y, Hassen W, and Chen S-H. A Novel Bystander Effect Involving Tumor Cell Derived Fas and FasL Interactions Following AdHSV-tk and Ad.mIL-12 Gene Therapies in Experimental Prostate Cancer. Gene Ther. 9: 511-517, 2002.

## CONCLUSIONS

Studies thus far have supported the hypothesis that the combination of Ad.mIL-12 and Ad.FasL would be beneficial in controlling locally aggressive prostate cancers. And reconfirmed the ability of IFN- $\gamma$  to influence Fas-mediated cell death in human cell lines. We have now identified the CPP32 family of caspases as the important mediator of these events. The delineation of the exact pathway is nearly complete and we should soon finish construction of the prostate specific FasL virus.

IFN- $\gamma$  SENSITIZATION OF PROSTATE CANCER CELLS TO FAS-MEDIATED DEATH:  
A GENE THERAPY APPROACH

William A. Selleck<sup>2</sup>, Steven E. Canfield<sup>2</sup>, Waleed A. Hassen<sup>2</sup>, Alexei I. Kuzmin<sup>1</sup>,  
Randy C. Eisensmith<sup>1</sup>, Shu-Hsia Chen<sup>1</sup>, and Simon J. Hall <sup>1,2</sup>.

<sup>1</sup>The Carl C. Icahn Institute for Gene Therapy and Molecular Medicine and <sup>2</sup>Department of  
Urology, Mount Sinai School of Medicine, New York, New York.

Key Words: Prostate Cancer, Gene Therapy, Fas, FasL, IFN- $\gamma$ , IL-12

Running Title: Ad.FasL Gene Therapy

Contact Address:      Simon J. Hall  
The Carl C. Icahn Institute for Gene Therapy and Molecular Medicine  
Box 1496  
Mount Sinai School of Medicine  
One Gustave Levy L. Place  
New York, N.Y. 10029  
Phone: 212-659-8267  
Fax: 212-803-6740  
E-Mail: halls01@doc.mssm.edu

## Abstract

While human prostate cancers and cell lines express Fas, most of these cell lines are resistant to Fas-mediated death. The present studies addressed the ability of IFN- $\gamma$  to influence Fas-mediated cell death in prostate cancer cells. In vitro exposure of the human cell lines, LNCaP and PC3 and the mouse cell line, RM-1, to agonist anti-Fas antibody and/or soluble Fas ligand resulted in killing of only PC3 cells. However, pre-incubation with IFN- $\gamma$  resulted in synergistic killing in all 3 cell lines. In vitro treatment of RM-1 with a replication incompetent adenovirus expressing mouse FasL (Ad.FasL) resulted in maximal cell kill near 40%, which correlated with baseline Fas expression. The addition of IFN- $\gamma$  enhanced cell kill to a degree consistent with the resulting higher levels of Fas and maintained synergistic killing at very low doses of vector. Co-inoculation of orthotopic RM-1 primary tumors with Ad.mFasL and an adenovirus expressing mouse IL-12 (Ad.mIL-12) to drive host production of IFN- $\gamma$  negated the survival advantage of Ad.mIL-12 alone. However, the staggered injection of Ad.mIL-12 and Ad.FasL achieved almost 3 fold higher levels of apoptosis in primary tumor tissue and doubled median survival. Therefore, IFN- $\gamma$  is capable of bestowing increased sensitivity to Fas-mediated cell death in prostate cancer cells and in a gene therapy approach define a powerful tool to treat prostate cancers.

## Introduction

Gene therapy offers the ability to kill tumor cells through a variety of distinct strategies including tumor suppressor gene therapy, pro-drug activation gene therapy and immunomodulatory gene therapy (1). The success of *in situ* gene therapy relies on the transduction of sufficient tumor cells with transgene to achieve tumor control; this has been a particularly difficult practical hurdle to overcome *in vivo*. In many instances successful approaches have exploited a bystander effect - the ability to kill more cells than were transduced with transgene. In general these strategies achieve this phenomenon by increasing exposure of surrounding, non-transduced tumor cells to cytotoxic byproducts, either through a cell mediated process such as with HSV-tk plus ganciclovir, or local diffusion such as with cytosine deaminase plus 5-fluorocytosine (1). Targeting specific markers unique to cancer cells would attain more specific and efficient killing. Indeed, immunotherapy employs inherent characteristics of tumor specific antigens to mark cancer cells for death. In a similar vein the redirection of vectors to cancer cell specific membrane-bound molecules would allow for restrictive transduction. Yet to date, few such candidate targets have been identified.

Fas is a potential target expressed on the cell surface of many tumor cells. The binding of its ligand, FasL, initiates an intracellular cascade resulting in apoptosis (2) It is unknown why many tumors, including prostate, express Fas, but its use as a therapeutic target has generated interest. The idea of exploiting the Fas/FasL pathway as a vehicle for killing prostate cancer cells arose from studies exploring the mechanisms of local and systemic growth suppression observed following injection of an adenovirus expressing IL-12 (Ad.mIL-12) in an orthotopic mouse model of prostate cancer (3). Studies linked the ability of IL-12 to direct host production of measurable serum levels of IFN- $\gamma$  which in turn significantly increased tumor cell expression of Fas but not FasL. *In vitro* IFN- $\gamma$  resulted in a dose-dependent cell death due to the interaction of low constitutive FasL expression and high Fas expression (3). *In vivo* blockade of Fas/FasL interactions resulted

in a modest reduction in primary tumor killing, a site of inherently low FasL expression, and a significant loss in suppression of metastatic lesions in the lung, a site of high FasL expression (3). By immunohistochemistry, however, most of the surviving primary tumor cells remained Fas+ and thus targets for FasL transactivation. Therefore, a hypothesis was generated that in the face of high Fas expression relatively lower levels of FasL expression, as would be achieved by *in situ* gene therapy, may mediate higher levels of growth suppression due to the ability of a single FasL-expressing cell to kill many surrounding Fas-expressing cells.

Immunohistochemical studies have shown that human prostate cancers express Fas (4-7). Established human prostate cancer cell lines have also been found to express Fas, though most are generally resistant to Fas transactivation by agonist antibody (4, 5, 8). Initial studies noted the ability of IFN- $\gamma$  to enhance or restore sensitivity to Fas transactivaton in prostate cancer cells. Alone, a replication incompetent adenovirus expressing FasL resulted in modest killing, reflective of baseline expression of Fas. In the presence of IFN- $\gamma$ -mediated high Fas expression, markedly enhanced killing was experienced *in vitro*, even at low vector doses. In an aggressive orthotopic model of prostate cancer a staggered dosing of Ad.mIL-12 and Ad.FasL could result in significant increases in apoptosis and a doubling of mean survival.

## Materials and Methods

### Cell Lines:

The RM-1 cell line, an androgen insensitive mouse prostate cancer cell line, was established from a ras+ myc induced primary tumor, derived in the mouse prostatic reconstitution model in C57BL/6 mice (9, 10 - Obtained from Dr. Timothy Thompson, Baylor College of Medicine, Houston, TX). RM-1 cells are grown in DMEM with 10% FBS, penicillin (100 U/ml) and streptomycin (100mg/ml). LNCaP and PC-3, human prostate cancer cells (obtained from ATCC), were grown in RPMI 1640 or DMEM, respectively, supplemented with 10% FBS, penicillin (100 U/ml) and streptomycin (100mg/ml). TC268, a human sarcoma cell line, (11 - Obtained from Dr Nicholas Mistsiades, NIH) and 293 cells, a human embryonic kidney cell line, were grown in DMEM with 10% FBS, penicillin (100 U/ml) and streptomycin (100mg/ml). Jurkat cells (obtained from ATCC), a human T cell leukemia cell line, were grown in RPMI 1640 supplemented with 10% FBS. Cells were passaged by trypsinization and maintained with routine media changes. All media was obtained from CellGro (Mediatech, Herndon, VA).

### The Influence of IFN- $\gamma$ on Fas Sensitivity In Vitro:

Fas-mediated cytotoxicity in RM-1, PC3 and LNCaP cells was first addressed by exposing plated cells to PBS or IFN- $\gamma$  (recombinant human or mouse, Pharmingen, San Diego CA) for twenty-four hours. Each treatment group was then randomized to agonist anti-Fas IgG (10ug/ml, either hamster anti-mouse or mouse anti-human, Pharmingen) or isotype control IgG (hamster or mouse, 10ug/ml, Pharmingen). Viable cells, as per trypan blue exclusion, were counted the following day.

The ability to kill LNCaP or PC3 cells through Fas transactivation was also ascertained by exposing plated cells to soluble human FasL (sFasL). Soluble FasL was derived by concentrating media from TC268 sarcoma cells, which are known to excrete

active sFasL into conditioned media, as previously described (11). Twenty-five 20cm plates of TC268 or 293 cells (sFasL negative) were prepared. When cells were 80% confluent, plates were washed 2 times with PBS and fresh serum-free media applied for a 4 hour wash. Fresh serum free media was then applied and harvested 48 hours later. Media was then centrifuged at 2,000 rpm for 5 minutes to remove cellular debris. The resulting supernatant was concentrated 30 fold with Centriprep-10 filters (Amicon, Beverly, MA). PC3 and LNCaP cells were grown in regular media or media + 200u/ml IFN- $\gamma$  for 24 hours, followed by labeling with chromium ( $^{51}\text{Cr}$ ). A known number of targets were plated and exposed at a 1:1 volume ratio with TC268 concentrated media (+sFasL) or 293 cell concentrated media (No sFasL) for 18 hours. To serve as a positive control , Jurkat cells were labeled with  $^{51}\text{Cr}$  as above and exposed to concentrated media from either TC268 or 293 cells for 18 hours. The percentage of specific lysis was calculated as (experimental release-spontaneous release)/(maximal release-spontaneous release) from gamma counter measurements of supernatant harvested by the Skatron system (Skatron Instruments Inc, Va).

#### Adenoviral Vectors:

To construct a replication incompetent adenovirus-expressing mouse FasL, the FasL mRNA was amplified by PCR, followed by ligation into an adenovirus backbone driven by the Rous Sarcoma Virus promoter. The pAd.RSV-FasL was co-transfected with pBHG10 in 293 cells by the calcium phosphate precipitation method to yield Ad.FasL. To inhibit apoptosis of Fas+ 293 cells during the entire process, culture media was supplemented with the general caspase inhibitor, Z-VAD-FMK (20uM Enzyme System Products, Livermore, CA). Replication incompetent adenoviruses expressing either mouse IL-12 (Ad.mIL-12) or  $\beta$ -galactosidase (Ad. $\beta$ -Gal), a vector control, were constructed as previously described (12-14). Large scale production of vector was achieved following expansion in 293 cells and double cesium gradient ultracentrifugation purification. The

viral titer was ascertained in 293 cells via a plaque assay and expressed as plaque-forming units (pfu) per ml.

In vitro Cytotoxicity of Ad.FasL:

The potential for FasL alone or in combination with IFN- $\gamma$  to mediate toxicity in vitro was assayed by pre-incubating for 24 hours in INF- $\gamma$  (25 or 50 u/ml, Pharmingen) or PBS. The following day each group was subdivided for a one-hour exposure to escalating doses of Ad.FasL or Ad. $\beta$ -Gal. Dosing of virus was defined in terms of the multiplicity of infection (MOI = number of pfu per cell). Cells were harvested 24 hours later and viable cells, as determined by trypan blue (0.4%. Sigma Chemical Company, St. Louis. MO) exclusion were counted.

In Vivo Gene Therapy:

Orthotopic tumors were induced and treated with adenoviral vectors, as previously described (15). Briefly, tumors were induced by an injection of 7500 RM-1 cells into the dorso-lateral prostate of adult c57/BL6 mice (Jackson Laboratories). Visible tumors were then (co-)injected with vector on day 6, as per routine. All such procedures were performed under pentobarbital-induced anesthesia (50mg/kg). Endpoints for studies were either sacrifice at 14 days post-tumor cell inoculation with recording of tumor wet weight or longer term survival analysis. For survival studies animals either were found dead or were sacrificed when tumors were thought by palpation to approach 10% body weight or individual animals appeared stressed by weight loss, ruffled fur and/or lethargy. Where indicated, alternative vector injection schemes were followed. In some studies Ad. $\beta$ -gal or Ad.FasL were injected into the primary tumor a second time on day 9. Alternatively, either Ad. $\beta$ -Gal or Ad.mIL-12 were injected into the non-tumor bearing contra-lateral prostate lobe, while either Ad. $\beta$ -gal or Ad.FasL were injected into the tumor on day 6 and/or 9. In other studies repetitive staggered injections of either Ad.FasL or Ad. $\beta$ -Gal were performed

by the following protocol: day 6, injection of tumor with Ad. $\beta$ -Gal or Ad.mIL-12, and days 8 and 11, injection with Ad. $\beta$ -Gal and/or Ad.FasL.

Detection of Apoptosis In Vivo.

At indicated times animals were sacrificed and primary prostate tumors fixed in 10%, embedded in paraffin, and sectioned. After sectioning tissues were stained with hematoxylin and eosin for routine histopathologic screening. Presence of apoptotic activity was achieved by TUNEL assay as per manufacturers instructions (Trevigne Industries, Gaithersburg, MD). The number of positive bodies were counted at 400x by viewing across the long and short axis of tissue sections and expressed as number of bodies per high power field (HPF).

## Results

### Effects of IFN- $\gamma$ on Fas-Mediated Toxicity *In Vitro*

Studies first explored the effect of IFN- $\gamma$  on Fas-mediated cytotoxicity in 3 different prostate cancer cell lines. Agonist anti-Fas antibody alone demonstrated little killing of RM-1 cells, but the addition of a minimum dose of 50u/ml IFN- $\gamma$  resulted in a surviving fraction of 30+/-14% (Figure 1A: at 50u/ml IFN- $\gamma$  Control IgG versus anti-Fas IgG, p=0.0016, t-test). Higher doses of IFN- $\gamma$  did not further increase anti-Fas IgG-mediated killing. For PC3 cells, known to be sensitive to Fas transactivation, both IFN- $\gamma$  and anti-Fas IgG resulted in cell kill, 24+/-3% and 25+/-12% respectively (Figure 1B). The combination of IFN- $\gamma$  and anti-Fas IgG resulted in a surviving fraction of 36+/-6% (Control IgG+IFN- $\gamma$  or anti-Fas IgG alone versus IFN- $\gamma$ +anti-Fas IgG: p=0.0025, t-test). For LNCaP cells, known to be resistant to Fas transactivation, anti-Fas IgG alone had no effect but in combination IFN- $\gamma$  resulted in a surviving fraction of 42+/-13% (Figure 1B. Control IgG+IFN- $\gamma$  versus anti-Fas IgG+IFN- $\gamma$ , p=0.03, t-test). Similar results were experienced using sFasL instead of agonist anti-Fas IgG with PC3 and LNCaP cells, noting the marked enhancement of cell lysis by pre-exposure to IFN- $\gamma$  prior to Fas transactivation (Figure 1C. PC3: TC268 media +IFN- $\gamma$  versus TC268 media, p=0.0074, t-test. LNCaP: TC268 media +IFN- $\gamma$  versus TC268 media, p<0.0001, t-test). By this assay Jurkat cells were lysed 93+/-3% by TC268 media versus 5+/-2.3% for 293 media (data not shown).

Studies then addressed the effects of IFN- $\gamma$  on Fas expression as analyzed by FACS. Prior experience with RM-1 cells had noted a baseline expression of 30% which following exposure to 50u/ml of IFN- $\gamma$  resulted in increased expression of Fas to ~60-70% (3, 16). FACS analysis of PC3 and LNCaP cells noted baseline expression of Fas at 77% and 95%, respectively. Pre-incubation of both cell lines with IFN- $\gamma$  at 100u/ml did not increase Fas expression (data not shown).

### In Vitro Activity of Ad.FasL

Alone, Ad.FasL demonstrated dose dependent killing to a maximum of near 40%. (Figure 2A). At MOIs greater than 12.5 there was no further killing from this level, which correlates to the baseline expression of Fas (3). The effects of IFN- $\gamma$  were addressed at 2 doses, the higher of which enhanced the toxicity of control vector (Figure 2C). The combination of Ad.FasL and IFN- $\gamma$  at both doses resulted in enhanced cell kill over Ad.FasL alone (Ad.FasL versus Ad.FasL+IFN- $\gamma$  - 50u/ml: p=0.035 Mann-Whitney, 25u/ml: p=0.014 Mann-Whitney). The maximum cell kill of combination therapy correlates with the dose effect of IFN- $\gamma$  on Fas expression following cytokine exposure (3). Importantly, reducing Ad.FasL dose maintained more than additive effects through to MOIs of 1.5 (Figure 2B), indicating the presence of synergistic killing.

### In vivo Gene Therapy:

Initial studies focused on identifying the therapeutic dose of Ad.FasL in combination with a fixed dose of Ad.mIL-12. The dose of Ad.mIL-12 chosen,  $1 \times 10^9$  pfu, was 10 fold lower than the therapeutic dose of Ad.mIL-12 alone in the RM-1 model (3). Combination therapy demonstrated a significant suppression of tumor growth with Ad.FasL doses greater than  $5 \times 10^8$  pfu (Figure 3A,  $5 \times 10^8$  pfu vs.  $1 \times 10^9$  pfu, p=0.003, t-test). No additional benefit was derived from increasing viral doses above  $1 \times 10^9$  pfu. In fact higher, Ad.FasL doses trended for larger tumors, but this was not found to be statistically significant ( $1 \times 10^9$  pfu vs.  $1 \times 10^{10}$  pfu, p = 0.16, t-test).

Dose control experiments were performed to determine the relative effectiveness of individual treatments and combination gene therapy. Ad.FasL alone resulted in tumors which were 27%+/-11% smaller than controls (Figure 3B, p=0.04, t-test). Ad.mIL12 therapy resulted in tumors which were 54+/-7% smaller than control tumors (p=0.001,t-test). Combination gene therapy resulted in tumors which were 72+/-6% smaller than control tumors (Ad.mIL12 vs. Combination therapy, p=0.04, t-test).

In a survival study a single injection of Ad.FasL had no effect on survival (Figure 4A). Surprisingly a co-injection of Ad.FasL+Ad.mIL-12 was inferior to Ad.mIL-12 (Figure 4A, Ad.mIL-12: 22.8+/- .8 days vs combo Tx: 19.3+/- .6 days, p=0.0134, Mantel-Cox). A second injection of Ad.FasL on day 9 to target remaining Fas positive cells likewise worsened survival over that experienced with Ad.mIL-12 alone (Figure 4A). It was reasoned that perhaps combination therapy was inferior to Ad.mIL-12 alone due to the killing of Ad.mIL-12 transduced cells, thereby reducing both IL-12 and IFN- $\gamma$  levels, and/or to the killing of activated NK/T cells important in the longer-term growth suppression (3). To test this hypothesis Ad.mIL-12 was injected into the contralateral lobe of the prostate, which did not harbor a tumor, and Ad.FasL was injected into the tumor, as before. In this assay as would be predicted injection of the contralateral lobe with Ad.mIL-12 reduced the survival enhancing abilities of intratumoral cytokine therapy (Figure 4B). However, the addition of repetitive intratumoral injection of Ad.FasL resulted in significantly enhanced tumor growth suppression over intratumoral treatment with Ad.mIL-12 (Figure 4B, Ad.mIL-12 intratumoral versus Ad.mIL-12 contralateral + intratumoral FasL, p=0.027 Mantel-Cox). This study would indicate the need to either inject Ad.mIL-12 away remote from Ad.FasL injection or stagger the injections of Ad.mIL-12 and Ad.FasL. While the former would ensure serum levels of IFN- $\gamma$  to influence Fas expression, it also would not take advantage of the multi-faceted effects of IL-12 itself within the tumor.

This issue was addressed by injecting Ad.mIL-12 on day 6 as per protocol and injecting Ad.FasL on days(s) 8 and 11. Day 8 was chosen for the injection of Ad.FasL as it coincided with the peak serum level of IL-12 following vector injection (3). This study noted the superiority of combination therapy, especially with the second injection of Ad.FasL (Figure 4C, Ad.mIL-12+Ad.FasL - 2 doses versus Ad.mIL-12, p=0.0004 Mantel-Cox; Ad.mIL-12+Ad.FasL - 2 doses versus Ad.mIL-12+Ad.FasL - 1 dose, p 0.0015, Mantel-Cox). Overall, the combination of Ad.mIL-12 plus 2 doses of Ad.FasL

doubled mean survival over controls, 16+/- .89 days to 33+/-1.57 days (p=0.0003, Mantel-Cox).

Assay of Apoptosis in vivo:

Random mice from the staggered injection scheme (Figure 4C) representing each treatment group were sacrificed on day 11 or day 14 for analysis of apoptotic activity. Three days following vector injection Ad.FasL alone increased apoptotic activity by ~1.5x, while combination therapy doubled activity (Figure 5, Control versus Ad.FasL, p=0.036 t-test; Control versus combination therapy, p=0.0016, t-test; Ad.FasL versus combination therapy, p=0.028 t-test). Analysis of tissues 3 days following the second injection of Ad. $\beta$ -gal or Ad.FasL noted a near tripling (2.72x) of apoptosis by a 2<sup>nd</sup> injection in combination treated tumors compared to a doubling for tumor injected twice with Ad.FasL only (Figure 5, Ad.FasLx2 versus Ad.mIL-12+Ad.FasLx2, p=0.03 t-test).

## Discussion

A major practical issue of *in-situ* cancer gene therapy which must be addressed to ensure its success is the lack of high transduction efficiency following injection of a tumor. The approach of combining Ad.mIL-12 and Ad.FasL exploits the ability of a single injection of IL-12, which would transfect 25% of cells at best, to then influence a potential target on virtually all cells within the same tumor. Vector-mediated expression of FasL would thus be capable of killing many surrounding Fas+ cells. Such a process would represent a bystander effect as an important mechanism to achieve tumor control following *in situ* gene therapy. Results from the *in vitro* studies indicate that Ad.FasL alone results in the maximum killing of approximately 40% of the cells at the highest vector dose. This activity closely correlates to the constitutive level of Fas expression by RM-1 of 30% (3). The addition of IFN- $\gamma$  increased the level of maximum cell kill, shifted the attainment of maximum cell kill to a 2-fold lower vector dose and maintained significant cytotoxicity even at very low vector doses. At MOI 6.25 Ad.FasL alone caused cell loss of only 5% in combination with IFN- $\gamma$  resulted in nearly 60% cell loss. (Figure 1), indicating the presence of synergistic killing as hypothesized.

The *in vivo* experiments demonstrated the positive growth effects of manipulating Fas/FasL interactions but also demonstrated some of its limitations. The dose escalation of Ad.FasL noted a maximum effect with  $1 \times 10^9$  pfu and trended for less effect with higher doses. In initial survival studies co-injection of Ad.mIL-12 and Ad.FasL significantly negated the effects of Ad.mIL-12 therapy. One would postulate 2 underlying reasons for this phenomenon. First, it is possible that as greater numbers of cells are infected with FasL they are killed off too rapidly to exert any effect on surrounding Fas+ cells. Secondly, and more likely, FasL itself may neutralize some of the positive effects of IL-12. Experience with Ad.mIL-12 alone had noted several factors mediating growth responses in addition to increasing Fas expression including induction of neutrophil-

mediated apoptosis within the first 24-48 hours following injection and the induction of both NK and T cell responses after 7-8 days (3). These events undoubtedly were dependent on the ability of treatment to induce a double peak of IL-12: the first peak occurs on the 2nd day post-Ad.mIL-12 injection and the second peak occurring on the 8<sup>th</sup> day post-injection (3). Approximately, 2 days following each peak of IL-12, a similar peak of IFN-γ could be measured in serum of treated mice. The first cytokine peak was produced in response to the vector itself and the second by induced NK/T cell immune response (3). Therefore, it was reasoned that the presence of FasL at high concentrations within the prostate could first neutralize Ad.mIL-12 transfected/producing cells to reduce the levels of both IL-12 and IFN-γ, and secondly, the reductions of these cytokines would lessen the induction of NK/T cell responses critical to IL-12-mediated survival.

This hypothesis was addressed in 2 ways. The injection of Ad.mIL-12 into the non-tumor bearing contralateral prostate lobe but continuing the injection of Ad.FasL into the tumor maintained the interaction of IL-12-IFN-γ-Fas + FasL to result in superior growth effects over co-injection of both vectors into the cancer. In this scenario growth effects are obtained without any direct benefit from IL-12 itself and cleanly illustrates the power of Fas/FasL interactions in this aggressive model of prostate cancer. In the second scenario the vectors, Ad.mIL-12 and Ad.FasL are injected in a staggered fashion, directed to avoid high levels of FasL at the time of the 1<sup>st</sup> peak of IL-12 secretion. In this study the clear benefits of both Fas/FasL interaction combined with the effects of IL-12 are identified to increase apoptotic activity and double survival from 16+/-0.89 days to 33+/-1.57 days. An important caveat learned from these studies points to the need for careful thought when approaching combination strategies for cancer: some designs may actually be detrimental and should be assembled knowing the variety of pathways each may influence.

Exploitation of the interaction of Fas and its ligand, FasL to initiate an intracellular cascade resulting in apoptosis (2) has attracted interest by a variety of investigators against many cancers. However, use of soluble FasL or agonist-acting anti-Fas antibodies results in

severe toxicity due to the wide variety of vital tissues, primarily the liver, which express Fas, requiring restrictive expression of FasL (17). Furthermore, while virtually all of the human prostate cancer cells lines express Fas, most are resistant to Fas transactivation by agonist anti-Fas antibodies (4, 5, 8). Studies have demonstrated that the apoptotic pathway appears intact within these resistant cells, but is actively inhibited through an unknown mechanism (4, 18). The block of the apoptotic pathway appears too occur upstream of caspase 8 (19) and in co-mixing of resistant and sensitive cells lines the dominant nature of Fas resistance phenotype was demonstrated (20). Some investigators have found that use of vector mediated FasL expression increased Fas-mediated killing over that achieved by agonist antibody (21, 22), as was experienced with RM-1. Moreover, sensitization to Fas-mediated cell death has been achieved in many human prostate cancer cells by a variety of drugs, including adriamycin, etoposide, mitoxantrone, camptothecin, and VP-16, though the pathway(s) involved are unknown (5, 18, 23, 24). In the present study IFN- $\gamma$  enhanced Fas-directed cell kill in a sensitive cell line (PC3) and restored sensitivity in a resistant cell line (RM-1 and LNCaP) under conditions of both anti-Fas IgG (RM-1) and sFasL transactivation. In RM-1 the enhancement in cytotoxicity was directly related to increased expression of Fas as measured by FACS, the level of which closely correlated with the degree of cell kill. The human cell lines, however, demonstrated high levels of constitutive Fas, which were unchanged by IFN- $\gamma$  exposure. The mechanism behind this process is the subject of further investigation.

While much speculation can be made concerning the presence or absence of Fas sensitivity in the few human prostate cancer cell lines available, the status of Fas sensitivity in prostate cancer tissue in patients is entirely unclear. Most of the human cell lines have been derived from metastatic lesions, are highly passaged, and bear little resemblance to prostate cancers by other parameters. By immunohistochemistry human prostate tissue, both benign and malignant, express Fas but not FasL (4-7). Human cell lines derived from benign prostate tissue undergo apoptosis following infection with Ad.FasL and the injection

of normal rat prostate with Ad.FasL results in apoptosis of epithelial cells lining galndular acini (25). Analysis of cancer tissue obtained via laser capture microdissection noted LOH of the Fas gene in 31% of cases, but there was no relation between immunohistochemical analysis for Fas presence or absence and LOH (26). Therefore, until fresh explants of prostate cancers or epithelial cells from such tissues are analysed for Fas sensitivity this question will remain unanswered.

**Acknowledgements:**

This work was funded by a grant from the Department of Defense, DAMD PC-99-1108 to SJH.

## References

1. Hall SJ, Chen S-H, and Woo SLC. (1997) The Promise and Reality of Cancer Gene Therapy. *Am J Hum Genetics*, **61**: 785-789.
2. Hug H. (1997) Fas-mediated apoptosis in tumor formation and Defense. *Biol Chem*, **378**: 1405-1412.
3. Sanford MA, Yan Y, Canfield SE , Hassen W, Atkinson G, Chen SH, and Hall SJ. (2001) Independent Contributions of Gr-1+ Leukocytes and Fas/FasL Interactions to Induce Apoptosis Following IL-12 Gene Therapy in a Mouse Model of Prostate Cancer. *Hum Gene Ther* **12**: 1485-1498.
4. Rokhlin OW, Bishop GA, Hostager BS, Waldschmidt TJ, Sidorenko SP, Pavloff N, Kiefer MC, Umansky SR, Glover RA, and Cohen MB. (1997) Fas-mediated apoptosis in human prostatic carcinoma cell lines. *Cancer Res*, **57**: 1758-1768.
5. Liu QY, Rubin MA, Omene C, Lederman S, and Stein CA.(1998) Fas ligand is constitutively secreted by prostate cancer cells in vitro. *Clin Cancer Res*, **4**: 1803-1811.
6. Sasaki Y, Ahmed H, Takeuchi T, Moriyama N, and Kawabe K. (1998) Immunohistochemical study of Fas, Fas ligand and interleukin-1 beta converting enzyme expression in human prostatic cancer. *Br J Urol*, **81**: 852-855.
7. Diaz JI, Pow-Sang JM, Mora LB, Seigne JD, Cantor AB, and Dalton WS. (2000) Cytometric analysis of Fas and Bcl-2 expression in normal prostatic epithelium and prostate cancer.*Urol Oncol*, **5**: 149-154.

8. Hedlund TE, Duke RC, Schleicher MS, and Miller GJ. (1998) Fas-mediated apoptosis in seven human prostate cancer cell lines: correlation with tumor stage. *Prostate*, **36**: 92-101.
9. Thompson TC, Southgate J, Kitchner G, Land H. (1989) Multi-stage carcinogenesis induced by *ras* and *myc* oncogenes in a reconstituted organ. *Cell*, **56**: 917-930.
10. Baley PA, Yoshida K, Qian W, Sehgal I, and Thompson TC. (1995) Progression to androgen insensitivity in a novel *in vitro* mouse model for prostate cancer. *J Steroid Biochem Mol Biol* **52**: 403-413.
11. Mitsiades N, Poulaki V, Kotoula V, Leone A, and Tsokos M. (1998) Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase. *Am J Pathol*, **153**: 1947-1956.
12. Caruso M, Pham-Nguyen K, Kwong YL, Xu B, Kosai KI, Finegold M, Woo SL, and Chen SH. (1996) Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. *Proc Natl Acad Sci U S A*, **93**: 11302-11306.
13. Pham-Nguyen KB, Yang W, Saxena R, Thung SN, Woo SL, and Chen SH. (1999) Role of NK and T cells in IL-12-induced anti-tumor response against hepatic colon carcinoma. *Int J Cancer*, **81**: 813-819.
14. Stratford-Perricaudet LD, Makeh I, Perricaudet M, and Briand P. (1992) Widespread long-term gene transfer to mouse skeletal muscles and heart. *J Clin Invest*, **90**: 626-630.

15. Hall SJ, Mutchnik SE, Chen S-H, Woo SLC, and Thompson TC. (1997) Adenoviral Mediated Herpes Simplex Virus Thymidine Kinase Gene Transduction and Ganciclovir Therapy Leads to Inhibition of Spontaneous and Induced Metastasis in an Orthotopic Mouse Model of Prostate Cancer. *Int J Cancer*, **70**: 183-187.
16. Griffith TS, Kawakita M, Tian J, Ritchey J, Tartaglia J, Sehgal I, Thompson TC, Zhao W, and Ratliff TL. (2001) Inhibition of murine prostate tumor growth and activation of immunoregulatory cells with recombinant canarypox viruses. *J Natl Cancer Inst*, **93**: 998-1007.
17. Ogasawara J, Watanbe FR, Adachi M, Matsuzawa T, Kasugi Y, Kitamura Y, Itoh N, Suda T and Nagata S. (1993) Lethal effect of anti-Fas antibody in mice. *Nature*, **364**: 806-809.
18. Frost PJ, Belldegrun A, and Bonavida B. (1999) Sensitization of immunoresistant prostate carcinoma cell lines to Fas/Fas ligand-mediated killing by cytotoxic lymphocytes: independence of de novo protein synthesis. *Prostate*, **41**: 20-30.
19. Rokhlin OW, Hostager BS, Bishop GA, Sidorenko SP, Glover RA, Gudkov AV, and Cohen MB. (1997) Dominant nature of the resistance to Fas- and tumor necrosis factor- $\alpha$ -mediated apoptosis in human prostatic carcinoma cell lines. *Cancer Res*, **56**: 3941-3943.
20. Rokhlin OW, Glover RA, and Cohen MB. (1998) Fas-mediated apoptosis in human prostateic carcinoma cell lines occurs via activation of caspase-8 and caspase-7. *Cancer Res*, **58**: 5870-5875.

21. Hedlund TE, Meech SJ, Srikanth S, Kraft AS, Miller GJ, Schaack JB, and Duke RC. (1999) Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells. *Cell Death Differ*, **6**: 175-182.
22. Hyer ML, Voelkel-Johnson C, Rubinchik S, Dong J and Norris JS. (2000) Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis. *Mol Ther*, **2**: 348-358.
23. Uslu R, Borsellino N, Frost P, Garban H, Ng C-P, Mizutani Y, Belldegrun A, and Bonavida B. (1997) Chemosensitization of human prostate carcinoma cell lines to anti-Fas-mediated cytotoxicity and apoptosis. *Clin Cancer Res*, **3**: 963-972.
24. Costa-Pereira AP and Cotter TG. (1999) Camptothecin sensitizes androgen-independent prostate cancer cells to anti-Fas-induced apoptosis. *Br J Cancer*, **80**: 371-378.
25. Kirkman W, Chen P, Schroeder R, Feneley MR, Rodriguez R, Wickham TJ, King CR and Bruder JT. (2001) Transduction and apoptosis induction in the rat prostate using adenovirus vectors. *Hum Gene Ther*, **12**: 1499-1512.
26. Takayama H, Takakuwa T, Dong Z, Nonomura N, Okuyama A, Nagata S, and Aozasa K. (2001) Fas gene mutations in prostatic intraepithelial neoplasia and concurrent carcinoma: analysis of laser capture microdissected specimens. *Lab Invest*, **81**: 283-288.




## Figure Legends


1. Fas Transactivation of Prostate Cancer Cells In Vitro. A&B) Plated RM-1, PC3 and LNCaP cells were exposed to escalating doses of mouse or 100u/ml human IFN- $\gamma$  or PBS. Twenty-four hours later each treatment condition was randomized to receive either anti-Fas IgG or isotype control IgG (10ug/well). One day later viable cells as determined by trypan blue exclusion were counted. Each bar represents the average of triplicate wells+/- standard deviation (SD). C). Plated PC3 and LNCaP cells were exposed to 100 u/ml IFN- $\gamma$  or PBS and the following day loaded with  $^{51}\text{Cr}$ . Cells were then plated in 96 well plates in 50 ul media to which 50ul concentrated media from either 293 or TC 268 was added. Media was harvested and radioactivity measured 18 hours later. Each bar represents the average of triplicate wells+/-SD.
2. Effects of Ad.FasL on RM-1 Cells In Vitro. A) Plated RM-1 cells were transduced at escalating MOIs for 1 hour and the following day viable cells were counted. Each data point represents the average of triplicate wells +/-SD. B&C). Plated RM-1 cells were randomized to exposure to PBS or 25 or 50 u/ml of mouse IFN- $\gamma$ . The next day each treatment condition was randomized for transduction with escalating MOI of Ad. $\beta$ -Gal or Ad.FasL. Twenty-four hours later viable cells were counted. Each data point represents the average of triplicate wells +/-SD.
3. Effect of Ad.FasL and Ad.mIL-12 on Orthotopic Tumor Size. A). Established RM-1 tumors were injected with Ad.mIL-12 and escalating doses of Ad.FasL on day 6 post-tumor cell inoculation. All mice were sacrificed on day 14 and the wet weight of each tumor recorded. Each bar represents the average +/- SD. (n=5 for each group). B) Established RM-1 tumors were randomized for injection with either Ad. $\beta$ -Gal, Ad.FasL, Ad.mIL-12 or


Ad.FasL+Ad.mIL-12 on day 6. All mice were sacrificed on day 14 and the wet weight of each tumor recorded. Each bar represents the average +/- SD. (n=6 per group).

4. Effect of Ad.FasL and Ad.mIL-12 on Survival. A) Established orthotopic tumors were randomized for injection with Ad. $\beta$ -Gal, Ad.FasL, Ad.mIL-12 or Ad.FasL+Ad.mIL-12 on day 6. Mice were followed until death or sacrifice due to stress. (n=6-7 per group). B) Mice with established orthotopic tumors were randomized on day 6 for intratumoral injection with Ad.FasL, Ad.mIL-12, or Ad.FasL+Ad.mIL-12 and/or contralateral injection into the normal dorsolateral prostate with Ad.mIL-12 or Ad. $\beta$ -Gal. Some mice injected with Ad.mIL-12 in the contralateral lobe were re-injected on day 9 with either Ad.FasL or Ad. $\beta$ -gal. Mice were then followed as above. (n=6-7 per group). C) Established orthotopic tumors were randomized for Injection with either Ad. $\beta$ -gal or Ad.mIL-12 on day 6. Each group was then further randomized to receive an injection with either Ad. $\beta$ -Gal or Ad.FasL on day 8. In addition some mice were re-injected with either Ad. $\beta$ -gal or Ad.FasL on day 11. Mice were then followed as above. (n=6-7 per group).

5. Effect of Staggered Vector Dosing on Apoptosis. Animals from each treatment arm were sacrificed on either day 11 or day 14 and the primary tumors prepared for paraffin embedding, sectioning and TUNEL assay. Specimens harvested on Day were only injected with Ad.FasL or Ad. $\beta$ -gal once , while those from day 14 were injected twice. Tumor sections were scanned across both long and short axes and the number of apoptotic bodies per HPF per tissue section recorded. For each treatment condition at the 2 time points each bar represents the average number of apoptotic bodies per HPF +/-SD. (n=4 tumors per time point and treatment condition)

**A****B****C**





RESEARCH ARTICLE

# A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer

SJ Hall<sup>1,2</sup>, SE Canfield<sup>2</sup>, Y Yan<sup>1</sup>, W Hassen<sup>2</sup>, WA Selleck<sup>2</sup> and S-H Chen<sup>1</sup>

<sup>1</sup>The Carl C Icahn Institute for Gene Therapy and Molecular Medicine, Mount Sinai School of Medicine, New York, NY, USA; and

<sup>2</sup>Department of Urology, Mount Sinai School of Medicine, New York, NY, USA

To enhance the NK population induced by Herpes Simplex virus thymidine kinase (HSV-tk) gene transduction and ganciclovir (GCV) treatment, adenovirus-mediated (Ad) expression of IL-12 was added to Ad.HSV-tk + GCV as combination gene therapy. This approach resulted in improved local and systemic growth suppression in a metastatic model of mouse prostate cancer (RM-1). In vitro assay of tumor infiltrating lymphocytes noted superior lysis of both RM-1 and Yac-1 targets with combination therapy, but in vivo depletion of NK cells only negatively impacted on systemic growth inhibition. TUNEL assay of primary tumors noted induction of apoptosis between two and four times higher than controls lasting for 6–8 days post-vector injection. After demonstrating that Ad.HSV-tk/GCV and Ad.mIL-12-induced IFN- $\gamma$  independently up-regulated expression of FasL and Fas, respectively, studies examined tumor cell-mediated death through Fas/FasL-induced apoptosis as a mechanism

of primary tumor growth suppression. In vitro, combination therapy at low vector doses resulted in synergistic growth suppression, which could be negated by the addition of anti-FasL antibody. In vivo co-inoculation of an adenovirus expressing soluble Fas resulted in combination therapy-treated tumors, which were three times larger than expected, and a reduction in apoptosis to baseline levels. In FasL knockout mice, combination therapy maintained the superior results experienced in wild-type mice, indicating that tumor cell, not host cell FasL, was responsible for Fas transactivation. Therefore, the combination of Ad.HSV-tk/GCV + Ad.mIL-12 results in enhanced local growth control via apoptosis due to tumor cell expression of Fas and FasL and improved anti-metastatic activity secondary to a strong NK response.

Gene Therapy (2002) 9, 511–517. DOI: 10.1038/sj/gt/3301669

**Keywords:** prostate cancer; gene therapy; Fas; FasL; HSV-tk; IL-12

## Introduction

Pro-drug activation gene therapy using Herpes Simplex virus thymidine kinase (HSV-tk) gene transduction in combination with ganciclovir (GCV) is under investigation as a potential cancer therapy. Intrinsic to its ability to control growth in a variety of tumor models has been the observation that anti-tumor immunity is induced, as manifest by inhibition of challenge injections or synchronously growing tumors.<sup>1–5</sup> While the steps involved in the initiation of an immune response following HSV-tk/GCV remain unclear, efforts to enhance this response have involved the empiric addition of cytokines, such as IL-2, to stimulate cytotoxic T cells and GM-CSF to enhance antigen presentation. In some tumor models such combinations have yielded superior results,<sup>6–9</sup> though in some models no improvement over HSV-tk/GCV was noted.<sup>10</sup> In an orthotopic mouse model

of prostate cancer adenovirus-mediated (Ad.) HSV-tk/GCV therapy resulted in the induction of natural killer cells (NK) within tumor infiltrating lymphocytes.<sup>11</sup> Performance of gene therapy in mice lacking NKs modestly reduced the impact of Ad.HSV-tk/GCV within the injected primary tumor and completely abrogated systemic growth suppression of pre-established metastatic deposits.<sup>11</sup>

The strategy of combining HSV-tk with IL-12 gene therapy was conceived to exploit the ability of IL-12 to stimulate NK proliferation and cytotoxicity,<sup>12</sup> to thereby further the innate immune response induced by Ad.HSV-tk + GCV. Parallel studies had demonstrated the individual growth suppressive ability of adenovirus-mediated IL-12 gene therapy (Ad.IL-12) to result in growth inhibition of both the injected tumor and pre-established metastases in a dose-dependent manner.<sup>13</sup> High-dose IL-12 therapy mediated growth suppression within the primary tumor through induction of innate (neutrophils and NKs) and acquired immunity (T cells), while anti-metastatic activity was mediated through up-regulation of Fas thereby enhancing sensitivity to FasL transactivation by lung epithelial cells.<sup>13</sup> The combination of Ad.HSV-tk and

Correspondence: SJ Hall, The Carl C Icahn Institute for Gene Therapy and Molecular Medicine, Box 1496, Mount Sinai School of Medicine, One Gustave Levy Place, New York, NY 10029, USA

Received 8 November 2001; accepted 17 December 2001

Ad.IL-12 illustrated the superior benefits of combination therapy to result in primary tumors which were 85–90% smaller than control tumors and a 75% reduction in the number of pre-established lung metastases.<sup>14</sup> Since prior work had noted the ability of both therapies to independently direct systemic growth suppression,<sup>11,13</sup> the strength of systemic anti-tumor activity mediated by combination therapy was tested by increasing the metastatic tumor burden to a point where neither AdHSV-tk/GCV nor Ad.IL-12 had a significant effect. In this setting, combination gene therapy continued to suppress the number of lung metastasis by 50%.<sup>14</sup>

In the present report, the underlying mechanisms of combination therapy are elucidated. AdHSV-tk/GCV + Ad.IL-12 enhanced NK activity, but performance of therapy in the absence of NK cells negatively impacted only on systemic growth suppression. TUNEL analysis noted the induction and maintenance of apoptosis by combination therapy. The resulting studies noted the independent ability of HSV-tk/GCV and IL-12-induced IFN- $\gamma$  to up-regulate tumor cell expression of FasL and Fas, respectively. Blockage of Fas/FasL interactions both *in vitro* and *in vivo* significantly blunted the effects of combination therapy. Performance of combination therapy in FasL knockout mice maintained the superior results of combination therapy to that experienced in wild-type mice, indicating that tumor cell, not host cell, FasL was responsible for Fas transactivation.

## Results

Assay of TIL harvested post-vector injection noted lytic activity in the AdHSV-tk/GCV, Ad.mIL-12 and AdHSV-tk/GCV + Ad.mIL-12 groups (Figure 1a and b). Induction of NK activity was noted initially in both groups treated with AdHSV-tk/GCV, peaking on day 4 post-vector injection and demonstrating superior activity for combination therapy ( $P = 0.006$ , *t* test, AdHSV-tk + GCV versus AdHSV-tk + GCV + Ad.mIL-12). As noted by past-experience,<sup>13</sup> Ad.mIL-12 therapy induced NK activity by day 8. TIL from both AdHSV-tk/GCV and combination gene therapy lysed RM-1s in a similar pattern, peaking on day 6 post-vector injection which again illustrated the superiority of combination gene therapy ( $P = 0.0054$ , *t* test, AdHSV-tk + GCV versus AdHSV-tk + GCV + Ad.mIL-12). The functional significance of this presumed NK response was explored by performing combination gene therapy in mice depleted of CD4 and CD8 T cells or NKs in the pre-established metastasis model. Assay over the first 8 days post-vector injection failed to demonstrate a negative impact with regard to primary tumor growth suppression following removal of T cells and NKs. In each instance tumors remained over five times smaller than control tumors ( $P < 0.0001$  for all conditions of combination therapy versus control, *t* test) (Figure 1c). However, suppression of pre-established metastases was completely lost in mice depleted of NK cells ( $P = 0.85$  versus control, *t* test), while the 50% reduction seen with combination treatment continued in mice depleted of T cells ( $P = 0.0001$  versus control, *t* test) (Figure 1d).


Serial assay for apoptosis noted enhanced activity in tumors treated with combination gene therapy, lasting for 8 days post-vector injection (Figure 2). By the 2nd day post-vector, all three treatment groups resulted in

increased apoptosis manifest by an eight times higher level for combination therapy compared with control, though appearing to be additive of the independent effects of Ad.mIL-12 and AdHSV-tk/GCV ( $P = 0.005$ , combination therapy versus control;  $P = 0.04$ , combination therapy versus Ad.mIL-12;  $P = 0.13$ , combination therapy versus AdHSV-tk/GCV, *t* test). In succeeding days apoptosis relating to Ad.mIL-12 resolved to control levels, while AdHSV-tk/GCV remained at approximately twice control and combination at four times control, ( $P < 0.05$  combination therapy versus control for days 4–8;  $P = 0.005$ , combination therapy versus AdHSV-tk/GCV for days 4 and 6, *t* test).


Studies with Ad.mIL-12 therapy alone in the RM-1 model noted measurable serum levels of IFN- $\gamma$ , which increased tumor cell expression of Fas both *in vitro* and *in vivo* (Figure 3).<sup>13,15</sup> In contrast IFN- $\gamma$  had little effect on FasL expression (Figure 3). Likewise, escalating doses of IL-12, 100 $\times$  higher than that measured in the serum of Ad.mIL-12-treated animals,<sup>13</sup> had no effect on Fas/FasL expression (Figure 3). Since HSV-tk/GCV has been reported to influence Fas and FasL expression in other tumor models,<sup>16,17</sup> the influence of AdHSV-tk/GCV was ascertained in RM-1 cells. FACS analysis of AdHSV-tk infected cells 24 h after exposure to GCV noted marked expression of FasL to approximately 50%. This correlated with the transduction efficiency of 40–50% at the vector dose used.<sup>18</sup> AdHSV-tk/GCV had little effect on Fas expression (Figure 3). Exposure to vector or GCV alone likewise had minimal influence on Fas/FasL expression (data not shown). By 48 h after GCV therapy, the number of surviving cells was reduced to 10–15%, with Fas/FasL resembling that of control (data not shown). A hypothesis was thus generated that the superior tumor control was due to the ability of IFN- $\gamma$ , produced in response to Ad.mIL-12, to enhance Fas expression and the ability of AdHSV-tk/GCV to enhance FasL, resulting in Fas transactivation and apoptosis within the primary tumor.

*In vitro* cell kill from AdHSV-tk/GCV at MOI of 25 is approximately 80% (Figure 4a). The addition of 25 U/ml IFN- $\gamma$ , a dose without growth suppressive activity itself, added no additional benefit at this vector dose. However, at progressively lower MOI the killing ability of AdHSV-tk/GCV lessened in a dose-dependent manner, but the addition of IFN- $\gamma$  maintained maximum cell kill to the MOI of 6.25 ( $P = 0.026$ , AdHSV-tk + GCV + IFN- $\gamma$  versus AdHSV-tk + GCV, Mann–Whitney). The addition of anti-FasL IgG at the time of GCV exposure blocked this effect such that the level of cell survival was identical to that of AdHSV-tk/GCV alone at all MOI tested (AdHSV-tk/GCV + IFN- $\gamma$  + anti-FasL IgG versus AdHSV-tk/GCV  $P = 0.63$ , Mann–Whitney; AdHSV-tk/GCV + IFN- $\gamma$  + anti-FasL IgG versus AdHSV-tk/GCV + IFN- $\gamma$ ,  $P = 0.0015$ , Mann–Whitney) (Figure 4b).

*In vivo* blockage of Fas/FasL interactions was achieved by co-inoculation with Ad.sFasIg at the time of AdHSV-tk + AdmIL-12 injection. Use of this vector significantly reduced the growth suppression of combination therapy such that tumors were three times larger than expected ( $P < 0.0001$ , combination therapy versus combination therapy + Ad.sFasIg) (Figure 4c). In addition, blockage of Fas/FasL interactions was associated with a loss of apoptosis generated by combination therapy. By day 8 post-vector apoptosis in combination therapy treated tumors was lowered to that of controls:  $1.73 \pm 0.22$  apop-



**Figure 1** NK induction following Ad.HSV-tk/GCV + Ad.mIL-12 gene therapy. (a and b) Fresh TIL were harvested 2, 4, 6 and 8 days after vector injection from Ad.HSV-tk/PBS, Ad.HSV-tk/GCV, Ad.mIL-12 and Ad.HSV-tk/GCV + Ad.mIL-12 treated tumors and exposed to 51Cr-labeled targets, YAC-1 (a) and RM-1 (b) cells. Each time point represents the effector:target ratio of 100:1 and the average of triplicate wells  $\pm$  s.d. (c and d) Tumor-bearing mice were randomized to receive i.p. injections of anti-NK IgG, anti-CD4 IgG + anti-CD8 IgG or control IgG 1 day prior to vector injection and continued as outlined in the text to deplete each population. Eight days after vector injection mice were killed and the tumor wet weight recorded (c) and the lung metastases counted. (d) Each bar represents the average of recorded data  $\pm$  s.d.




**Figure 2** Apoptosis following Ad.HSV-tk/GCV + Ad.mIL-12 gene therapy. Primary tumors from each treatment group were prepared for TUNEL assay on days 2, 4, 6 and 8 after vector injection. For each treatment condition, four tumors were examined and the number of apoptotic cells per HPF ( $\times 400$ ) was counted across the long and short axis of each tumor. The number of apoptotic cells per HPF for each tumor was then averaged for each condition and time point and graphed  $\pm$  s.d. The number of HPFs counted per tumor ranged from 5 at day 2 to 14 at day 8.

totic bodies/HPF for combination gene therapy,  $0.89 \pm 0.22$  apoptotic bodies per HPF for control, and  $0.89 \pm 0.17$  apoptotic bodies per HPF for combination gene therapy + Ad.sFasIg ( $P = 0.005$ , *t* test; combination gene therapy + Ad.sFasIg versus control,  $P = 0.98$ , *t* test). To verify that

the source of FasL was indeed tumor cells and not host sources, these studies were repeated in FasL knockout mice (Figure 4d). The marked growth suppression of Ad.HSV-tk/GCV + Ad.mIL-12 continued to the same degree as in wild-type mice with reversal only in the presence of Ad.sFasIg.

## Discussion

A variety of gene therapy strategies for the treatment of cancer have been developed, generally through one of two basic methods: local growth suppression via direct inoculation of tumor suppressor or pro-drug activation genes (ie p53 or HSV-tk) or systemic growth inhibition following local gene expression (ie antiangiogenesis gene therapy or gene-modified immunotherapy). A major limitation of *in situ* approaches is the low efficiency of vector uptake following direct injection, yielding it difficult to establish uniform cure rates. Attempts to bypass this problem have utilized intricate injection schemes, replication-competent vectors, and 'bystander effects', whereby more cells are killed than are transduced. The combination of Ad.HSV-tk/GCV and Ad.mIL-12 was chosen to exploit the ability of IL-12 to enhance proliferation and cytotoxicity of the NK response induced by HSV-tk + GCV in this model to improve both local and systemic




**Figure 3** FACS analysis of Fas/FasL expression following (a) IL-12, (b) IFN- $\gamma$ , and (c) HSV-tk/GCV therapy. Plated RM-1 cells were exposed to 25 U/ml IFN- $\gamma$ , 200 ng/ml IL-12, 50 MOI of Ad.HSV-tk or PBS. For (a) and (b), cells were prepared for immunostaining 24 h later with anti-Fas, anti-FasL, or control antibodies and FACS analysis. Cells exposed to Ad.HSV-tk were randomized to GCV or PBS treatments the following day and prepared for immunohistochemistry 24 h after GCV/PBS. For each graph the dotted line represents exposure to PBS and solid line the treatment condition.

growth suppression. Studies of TIL from combination therapy-treated mice indicated an enhancement of NK activity from Ad.HSV-tk/GCV alone by adding Ad.mIL-12. The *in vivo* relevance of this population was validated by a near complete loss of growth inhibition of pre-established metastatic lesions in the absence of NKs. Indeed, at the metastatic tumor burden tested the individual therapies had no effect on pre-established metastases,<sup>14</sup> indicating the strong systemic growth suppressive capabilities of this NK population.

While the control of disseminated lesions was dependent on NKs, the enhanced growth control of the injected tumor was not directly related to an immune response. Studies noted the independent ability of IFN- $\gamma$  and HSV-tk/GCV to influence Fas/FasL. RM-1 cells express both Fas and FasL (Fas approximately 25–30% and FasL approximately 10–15%); IFN- $\gamma$ at doses well below that

measured in serum of Ad.mIL-12-treated animals to upregulated Fas *in vitro* consistent with the literature.<sup>13,15</sup> *In vivo* increased Fas expression could be seen in Ad.mIL-12 injected tumors as early as 2 days post-vector, lasting to at least the 8th day (Ref. 13 and unpublished observations). In contrast high doses (up to 200 ng/ml) of recombinant IL-12 resulted in neither cytotoxicity<sup>13</sup> nor changes in Fas/FasL expression. In parallel, it has been shown that HSV-tk + GCV therapy may also influence Fas/FasL expression.<sup>16,17</sup> In a human neuroblastoma cell line HSV-tk/GCV resulted in apoptosis via FasL-independent aggregation of upregulated Fas.<sup>17</sup> In four different cancer cell lines HSV-tk/GCV increased expression of both Fas and FasL which mediated some degree of bystander killing, as documented by a reduction in HSV-tk/GCV effects by blockage of Fas/FasL interactions.<sup>17</sup> In three of four cases, Fas expression was more pronounced



**Figure 4** Fas/FasL interactions following combination therapy. (a) Plated RM-1 cells were exposed to escalating MOI of Ad.HSV-tk for randomization to PBS, PBS + IFN- $\gamma$  (50 U/ml), GCV or GCV + IFN- $\gamma$ . Viable cells were counted the following day. Each data point represents the average of triplicate wells  $\pm$  s.d. (b) The same groups as (a) were included, to which randomization included anti-FasL IgG or control IgG. Viable cells were counted the following day. Each data point represents the average of triplicate wells  $\pm$  s.d. (c and d) Primary tumors in wild-type (c) or FasL knockout mice (d) were injected with Ad.HSV-tk or Ad.HSV-tk + Ad.mIL-12 divided for co-inoculation with DL312 or Ad.sFasIg. The following day PBS or GCV as indicated was injected as outlined in the text. The wet weight of the primary tumor was recorded 8 days after injection. Each bar represents the average wet weight per group  $\pm$  s.d.

than FasL. In RM-1 cells Ad.HSV-tk + GCV more profoundly affected FasL with only a small increase in Fas expression. This effect was most pronounced 24 h after GCV exposure, a time defined by a large population of dying cells. Assay at 48 h noted only 10–15% surviving cells with Fas/FasL expression pattern identical to controls. The addition of anti-FasL antibody did not negatively impact on Ad.HSV-tk/GCV cytotoxicity, indicating, that Fas/FasL interactions do not play a role in a HSV-tk/GCV bystander effect in this cell line.

In vitro the addition of IFN- $\gamma$ , at a dose which itself does not impact on RM-1 cell growth, to Ad.HSV-tk + GCV, maintained maximum cell kill at a four-fold lower vector dose, indicating the presence of strong cooperative activities. The co-administration of an anti-FasL antibody reverses this phenomenon, clearly defining a role for Fas/FasL activities in this enhanced killing. Likewise, *in vivo* blockage of Fas/FasL results in a significant loss of growth suppression and apoptosis within the primary tumor, demonstrating that a proportion of enhancement due to combination therapy is related to Fas/FasL interactions. The correlation between loss of growth suppression and the decrease in apoptosis noted following use of Ad.sFasIg would suggest that apoptosis through Fas transactivation is the mechanism of cell death. While the hypothesis had placed the source of FasL as tumor

cells infected with Ad.HSV-tk and exposed to GCV, FasL could be derived from host sources *in vivo* such as immune cells (NK and/or T cells) or within prostate tissues.<sup>19</sup> Therefore, to further delineate the source of FasL, combination gene therapy was performed in FasL KO mice. As noted in wild-type mice, growth suppression with Ad.HSV-tk/GCV + Ad.mIL-12 resulted in a nearly 90% size differential with loss of activity achieved with the addition of Ad.sFasIg. Therefore, a tumor cell-mediated bystander effect is defined through Ad.HSV-tk/GCV and Ad.mIL-12-IFN- $\gamma$  independent induction of Fas and FasL expression to result in further killing through Fas transactivation. Both *in vitro* and *in vivo* studies illustrate the power of this phenomenon in combination gene therapy and characterize an additional approach to more efficiently kill cancer cells within the confines of an injected tumor.

## Materials and methods

### Cell lines

The RM-1 cell line (passage 14–17) is a well-characterized mouse prostate cancer cell line, established from a ras/myc-induced primary tumor derived in the mouse prostate reconstitution (MPR) model system in C57BL/6

mice (obtained from Dr TC Thompson, Baylor College of Medicine, Houston, TX, USA).<sup>20,21</sup> Cells used in the reported studies were grown in DMEM with 10% FBS and penicillin (100 units/ml) and streptomycin (100 mg/ml). YAC-1 is a NK cell-sensitive mouse lymphoma cell line, maintained in RPMI 1640 with 10% FBS. Routine passaging was carried out using cell dissociation media. All reagents pertaining to cell culture were obtained from Sigma (Sigma Chemical, St Louis, MO, USA).

#### Adenovirus vectors

Replication-defective E1 deleted recombinant adenovirus vectors expressing HSV-tk, mouse IL-12 (mIL-12), and sFasIg, all under control of the Rous sarcoma virus promoter (RSV), were constructed as previously described.<sup>13,22,23</sup> The Ad.sFasIg construct links the extracellular domain of Fas to the Fc region of mouse IgG2a. DL312 is an E1-deleted adenovirus without a transgene and was used as vector control. Virus titer for *in vivo* use was determined by plaque assay in 293 cells and expressed as plaque-forming units (p.f.u.) following expansion and double cesium gradient ultracentrifugation purification.

#### In vivo gene therapy

Orthotopic primary tumors and synchronous metastases were established as previously described.<sup>11</sup> Briefly, at the same sitting 7500 RM-1 cells were injected into the dorsolateral prostate and 7500 cells were injected via the dorsolateral tail vein. Primary tumors were injected with vector 6 days later, at which time the lungs contain microscopic metastases. The therapeutic dose of Ad.HSV-tk had been previously established at  $5 \times 10^8$  p.f.u.,<sup>5</sup> while Ad.mIL-12 was  $3.3 \times 10^9$  p.f.u. Mice were killed 14 days after tumor cell inoculation. The primary tumors were removed, the bladder and seminal vesicles excised, and a wet weight obtained for each tumor. The lungs were likewise removed, placed in Bouin's solution, and changed to 70% ethanol 1 h later. Visible lung metastases were counted with the aid of a dissecting microscope.

#### In vitro cytotoxic assays

At designated time-points, mice were killed, and the primary prostate tumors removed. Tumor infiltrating lymphocytes were extracted and prepared for chromium (<sup>51</sup>Cr) release assay, as previously described.<sup>11</sup> Briefly, pooled tumors from each treatment group were mechanically lysed and serially purified by gravity precipitation to remove tumor debris. Following treatment with red cell lysis buffer (Sigma) and passage through cotton wool pipettes, remaining viable lymphocytes were counted and exposed to <sup>51</sup>Cr-loaded targets at various E:T ratios. The percentage lysis was calculated as (experimental release - spontaneous)/(maximal release - spontaneous release) from the gamma counter measurements of supernatant harvested by the Skatron system (Skatron Instruments, Sterling, VA, USA).

#### In vivo depletions

Mice were depleted of specific lymphocyte populations by i.p. injections of antibodies beginning 1 day before Ad./HSV-tk + Ad.mIL-12 injection on a schedule as previously reported:<sup>11</sup> CD4 T cells with purified ascites from hybridoma GK 1.5 (American Type Culture Collection, Rockville, MD, USA), CD8 T cells with purified ascites

from hybridoma 2.43 (American Type Culture Collection), NK cells with anti-AsialoGM1 IgG (Wako Chemicals, Reston, VA, USA), and controls with rabbit IgG (DAKO, Carpinteria, CA, USA) and rat IgG (Accurate Chemical and Scientific, Westbury, NY, USA). Control mice were given a total of 20 µg of IgG to equal that given to CD4/CD8 mice. All mice were killed on day 14 with the removal of primary tumor and lungs with appropriate examination carried out as outlined above.

#### Apoptosis assay

Tumors representing each treatment arm, Ad.HSV-tk/PBS, Ad.HSV-tk/GCV, Ad.mIL-12, and Ad.HSV-tk/GCV + Ad.mIL-12, were harvested every other day beginning on day 2 after vector injection to 8 days after vector injection. In addition, tumors from mice treated with Ad.sFasIg alone or with combination therapy were killed 14 days after tumor inoculation and were similarly prepared. After fixation in formalin, paraffin embedding, and sectioning, tissue samples were prepared for TUNEL assay, according to the manufacturer's instructions (Trevigne Industries, Gaithersburg, MD, USA). Individual tumor sections were scanned along the long and short axes at high power ( $\times 400$ ) with a light microscope. The number of apoptotic bodies was counted and reported as average number of bodies per high power field.

#### FACS assay of Fas/FasL expression

Plated RM-1 cells were exposed to either mouse IFN-γ (100 U/ml, Pharmingen, San Diego, CA, USA), mouse IL-12 (1-200 ng/ml, Pharmingen) or Ad.HSV-tk at a multiplicity of infection (MOI: number of p.f.u. per cell) of 50. This vector dose correlates with approximately 50% cell transduction.<sup>18</sup> Twenty-four hours following the addition of IFN-γ, cells were removed with cell dissociation medium and prepared for immunohistochemistry. Cells exposed to vector were randomized 24 h later to saline (PBS) or GCV (10 µg/ml, Roche Laboratories, Nutley, NJ, USA). The following day, single cell suspensions were randomized to exposure to anti-FasL IgG, anti-Fas IgG, or iso-control IgG (Pharmingen) for 45 min on ice. Following washing in PBS, cells were exposed to PE-labeled anti-hamster IgG (Pharmingen) for 30 min followed by FACS analysis.

#### In vitro gene therapy

Plated RM-1 cells were exposed to escalating MOI of Ad.HSV-tk for 1 h. Twenty-four hours later, wells were randomized to receive PBS, GCV (10 µg/ml), mouse IFN-γ (25 U/ml) or GCV + IFN-γ. Disassociated viable cells as per trypan blue exclusion assay were counted the following day. Blockage of FasL/Fas interactions was achieved by adding anti-mouse FasL IgG or isotype control IgG (Pharmingen) to designated wells at the same time as the addition of PBS/GCV/IFN-γ.

#### Blockage of Fas/FasL interactions *in vivo*

Interference of Fas/FasL transactivation *in vivo* was achieved by co-inoculation with Ad.sFasIg, as previously described.<sup>13</sup> In the synchronous metastasis model on day 6, primary tumors were injected with either  $1 \times 10^9$  p.f.u. DL312 or Ad.sFasIg, followed by randomization for treatment with combination gene therapy or control vector. Mice were killed on the 8th day after vector injection and the effects of gene therapy measured in both the primary

tumor and lungs as described earlier. Further evaluation of Fas/FasL activities were carried out by repeating the same experiments in FasL knockout mice (Jackson Laboratory, Bar Harbor, ME, USA).

## Acknowledgements

These studies were supported by the Edwin Beer Award from the New York Academy of Medicine and DOD grant PC 99-1108, both to SJH, and NCI R01 CA70337 to SHC.

## References

- 1 Barba D, Hardin J, Sadelain M, Gage FH. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. *Proc Natl Acad Sci USA* 1989; **91**: 4348–4352.
- 2 Kianmanesh AR et al. A 'distant' bystander effect of suicide gene therapy: regression of nontransduced tumors together with a distant transduced tumor. *Hum Gene Ther* 1997; **8**: 1807–1814.
- 3 Bi W et al. An HSVtk-mediated local and distant antitumor bystander effect in tumors of head and neck origin in athymic mice. *Cancer Gene Ther* 1997; **4**: 246–252.
- 4 Yamamoto S et al. Herpes simplex virus thymidine/ganciclovir-mediated killing of tumor cells induces tumor-specific cytotoxic T cells in mice. *Cancer Gene Ther* 1997; **4**: 91–96.
- 5 Hall SJ et al. Adenoviral-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic model of prostate cancer. *Int J Cancer* 1997; **70**: 183–187.
- 6 Chen SH et al. Combination gene therapy for liver metastasis of colon carcinoma *in vivo*. *Proc Natl Acad Sci USA* 1995; **92**: 2577–2581.
- 7 Chen SH et al. Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. *Cancer Res* 1996; **56**: 3758–3762.
- 8 Coll JL et al. Long-term survival of immunocompetent rats with intraperitoneal colon carcinoma tumors using herpes simplex thymidine kinase/ganciclovir and IL-2 treatments. *Gene Therapy* 1997; **4**: 1160–1166.
- 9 Castleden SA et al. A family of bicistronic vectors to enhance both local and systemic antitumor effects of HSVtk or cytokine expression in a murine melanoma model. *Hum Gene Therapy* 1997; **8**: 2087–2102.
- 10 Felzmann T, Ramsey WJ, Blaese RM. Characterization of the antitumor immune response generated by treatment of murine tumors with recombinant adenoviruses expressing HSVtk, IL-2, IL-6 or B7-1. *Gene Therapy* 1997; **4**: 1322–1329.
- 11 Hall SJ, Sanford MA, Atkinson G, Chen SH. Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer. *Cancer Res* 1998; **58**: 3221–3225.
- 12 Hendrzak JA, Brunda MJ. Interleukin-12: biologic, activity therapeutic utility and role in disease. *Lab Invest* 1995; **72**: 619–637.
- 13 Sanford MA et al. Independent contributions of Gr-1+ leukocytes and Fas/FasL interactions to induce apoptosis following IL-12 gene therapy in a mouse model of prostate cancer. *Hum Gene Ther* 2001; **12**: 1485–1498.
- 14 Hassen W et al. Prospects for HSV-tk and cytokine gene transduction as immunomodulatory gene therapy for prostate cancer. *World J Urol* 2000; **18**: 130–135.
- 15 Weller M et al. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. *J Clin Invest* 1994; **94**: 954–964.
- 16 Beltinger C et al. Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases. *Proc Natl Acad Sci USA* 1999; **96**: 8699–8704.
- 17 Wei SJ et al. Involvement of Fas (CD95/APO-1) and Fas ligand in apoptosis induced by ganciclovir treatment of tumor cells transduced with herpes simplex virus thymidine kinase. *Gene Therapy* 1999; **6**: 420–431.
- 18 Eastham JA et al. Prostate cancer gene therapy: Herpes Simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate models. *Hum Gene Ther* 1996; **7**: 515–523.
- 19 Liu QY et al. Fas ligand is constitutively secreted by prostate cancer cells *in vitro*. *Clin Cancer Res* 1998; **4**: 1803–1811.
- 20 Thompson TC, Southgate J, Kitchner G, Land H. Multi-stage carcinogenesis induced by *ras* and *myc* oncogenes in a reconstituted organ. *Cell* 1989; **56**: 917–930.
- 21 Baley PA et al. Progression to androgen insensitivity in a novel *in vitro* mouse model for prostate cancer. *J Steroid Biochem Mol Biol* 1995; **52**: 403–413.
- 22 Chen SH et al. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated transfer *in vivo*. *Proc Natl Acad Sci USA* 1994; **91**: 3054–3057.
- 23 Caruso M et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. *Proc Natl Acad Sci USA* 1996; **93**: 11302–11306.

# Independent Contributions of GR-1<sup>+</sup> Leukocytes and Fas/FasL Interactions to Induce Apoptosis Following Interleukin-12 Gene Therapy in a Metastatic Model of Prostate Cancer

MICHAEL A. SANFORD,<sup>2</sup> YING YAN,<sup>1,2</sup> STEVEN E. CANFIELD,<sup>2</sup> WALEED HASSAN,<sup>2</sup> WILLIAM A. SELLECK,<sup>2</sup> GERTRUDE ATKINSON,<sup>1</sup> SHU-HSIA CHEN,<sup>1</sup> and SIMON J. HALL<sup>1,2</sup>

## ABSTRACT

In a mouse model of prostate cancer, adenovirus-mediated interleukin-12 (Ad.mIL-12) gene therapy resulted in significant growth inhibition of both the injected primary tumor and synchronous metastases. Within 2 days of vector injection, two distinct patterns of apoptosis were detected within the primary tumor, the inhibition of which with a caspase inhibitor substantially negated growth suppression. The dominant pattern displayed localized sheets of apoptotic cells in close association with necrosis containing polymorphic neutrophils (PMNs). Depletion of PMNs resulted in the loss of this pattern of apoptosis and reduced growth suppression. A second major wave of growth suppression within the primary tumor was mediated by an immune response. Natural killer (NK) cell activity was detected within tumor-infiltrating lymphocytes (TIL) by the eighth day post-vector injection, the depletion of which resulted in a significant loss of survival enhancement. A more modest role for T cells was identified, which in the absence of documented cytotoxic T lymphocyte (CTL) activity may be related to a significant reduction in interferon- $\gamma$  (IFN- $\gamma$ ) levels found in mice depleted of T cells, thereby reducing the secondary influences of IFN- $\gamma$ . However, depletion of NK cells or T cells had no discernible negative effect on IL-12-mediated anti-metastatic activity. Attention focused on the role of IFN- $\gamma$ , observed following Ad.mIL-12 therapy, to mediate the diffuse pattern of apoptosis seen in the primary and metastatic lesions. *In vitro* studies noted the ability of IFN- $\gamma$  to up-regulate tumor cell expression of Fas and FasL to mediate apoptosis, whereas *in vivo* blockage of Fas/FasL interactions with soluble Fas resulted in a modest reduction in primary tumor growth suppression but complete abrogation within metastatic lesions.

## OVERVIEW SUMMARY

The mechanisms underlying adenovirus-mediated interleukin-12 (Ad.mIL-12) gene therapy to support local and systemic growth suppression were explored in a mouse model of prostate cancer. Studies noted two phases of growth inhibition, apoptosis during days 2–6 post-vector injection and an immune response after day 8 post-vector injection. Likewise, apoptosis occurred in two distinct patterns, inhibition of which by a caspase inhibitor significantly reduced growth suppression in both the orthotopic and metastatic sites. The dominant pattern noted only in the primary tumor was associated with polymorphic neutrophils (PMN), which if depleted, resulted in a significant

loss of apoptotic activity and negation of local growth control. The later phase of growth suppression was mediated by natural killer (NK) and T cell responses. Although enhancement of animal survival correlated most closely with an NK response, abrogation of T cell activity had a less profound effect and in the absence of detectable cytotoxic T cell (CTL) activity loss of activity may be due to significantly less production of interferon- $\gamma$  (IFN- $\gamma$ ) in these animals. A second pattern of diffuse apoptosis was noted within primary tumors between areas of necrosis and was the sole pattern observed in metastases. Studies demonstrated the ability of IFN- $\gamma$  following IL-12 therapy to up-regulate Fas initiating Fas/FasL interactions to control metastatic growth.

<sup>1</sup>The Institute for Gene Therapy and Molecular Medicine and <sup>2</sup>Department of Urology, Mount Sinai School of Medicine, New York, NY 10029.

## INTRODUCTION

INTERLEUKIN-12 (IL-12) is a multifunctional cytokine that mediates a range of functions which may be useful in cancer treatment. Primarily, it directs Th1 differentiation of immune responses and enhances the proliferation and cytotoxicity of T cells and natural killer (NK) cells, dependent to a large degree on production of interferon- $\gamma$  (IFN- $\gamma$ ) by these effectors to maintain activity (Zeh *et al.*, 1993; Nastala *et al.*, 1994; Hendrzak and Brunda, 1995). On the basis of these influences, interest in using IL-12 treatment for cancer has focused on inducing antitumor immunity. In numerous cancer models, IL-12 treatment, either as recombinant protein or through a variety of gene therapy approaches, has demonstrated active growth inhibition of solitary tumors and may result in systemic growth suppression through inhibition of experimental metastases and/or resistance to challenge tumor cell injections (Brunda *et al.*, 1993; Tahara *et al.*, 1995; Bramson *et al.*, 1996; Colombo *et al.*, 1996; Rakhamilevich *et al.*, 1996; Tan *et al.*, 1996; Cui *et al.*, 1997; Coughlin *et al.*, 1998; Nanni *et al.*, 1998; Siders *et al.*, 1998; Nasu *et al.*, 1999; Hirschowitz *et al.*, 1999; Mendiratta *et al.*, 1999; Pham-Nguyen *et al.*, 1999; Cavallo *et al.*, 1999). Assays for T cells, NK cells, and NKT cells have validated individual and, in some instances, cooperative roles for these immune effectors in growth suppression. A further major component of tumor growth inhibition has been attributed to the ability of IFN- $\gamma$  to mediate anti-angiogenic activity through expression of inhibitors such as IFN- $\gamma$ -inducible protein-10 (Voest *et al.*, 1995; Sgadari *et al.*, 1996; Coughlin *et al.*, 1998). Secondary, less well understood mechanisms have also been proposed as potential mechanisms underlying IL-12 therapy. Treated tumors contain polymorphic neutrophils (PMNs) and macrophages that may influence tumor growth suppression (Tsung *et al.*, 1997; Cavallo *et al.*, 1999; Mendiratta *et al.*, 1999; Nasu *et al.*, 1999). IL-12 therapy may result in antiangiogenesis through down-regulation of proangiogenic substances such as vascular endothelial growth factor (VEGF) and matrix metalloproteinases (Dias *et al.*, 1998) or result in local cytotoxicity through tumor cell production of substances such as nitric oxide (Yu *et al.*, 1996). Last, IL-12 may directly alter cell motility and invasiveness which may impact on spontaneous metastatic behavior as a method of inhibiting metastases (Hiscox *et al.*, 1995). Yet, a comprehensive understanding of potential interactions or temporal relationships or degree of influence of these various mechanisms is lacking. Furthermore, it is unclear how these varying mechanisms correlate with the proximity to the site of gene transduction.

With approximately 180,000 diagnoses and 32,000 deaths attributed to prostate cancer in 2000 in the United States, this disease remains a serious public health issue (Greenlee *et al.*, 2000). Patients diagnosed with clinically localized disease may be offered definitive therapy in the form of radical surgery or radiation therapy. However, long-term freedom of disease as measured by a rising serum prostate-specific antigen (PSA) notes recurrence rates approaching 50% in higher-risk patients as defined by an initial PSA > 10 or presence of higher-grade disease (gleason score  $\geq 7$ ) on prostate biopsy (Catalona *et al.*, 1999). Similar results may be experienced with radiation therapy indicating the need for neo-adjuvant or adjuvant therapies in these patients to target both locally advanced primary and unrecognized microscopic metastatic disease. RM-1 is a mouse

prostate cancer cell line established from a primary prostate tumor derived in the mouse prostate reconstitution model system (Thompson *et al.*, 1989) and has been a useful tool for pre-clinical studies exploring gene therapy approaches to prostate cancer therapy. In this model, a single injection of adenovirus-mediated (Ad.m)IL-12 resulted in significant growth inhibition of both a primary tumor and pre-established metastases. Different mechanisms were responsible for growth suppression relating to chronology and proximity to IL-12 gene expression. Within the primary tumor several mechanisms sustaining growth suppression were defined, dominated within the first 2 days of vector injection by apoptosis due to an influx of GR-1 $^+$  leukocytes. Long-term growth suppression was mediated by a NK response noted within tumor infiltrating lymphocytes (TIL) induced 8 days post-vector injection and to a lesser extent a T cell response. Less significant within the injected tumor, but mediating the growth suppression within metastatic lesions, were the tumor cell-directed Fas/FasL interactions that were secondary to the ability of IL-12-directed host production of IFN- $\gamma$  to up-regulate both Fas and FasL expression on RM-1 cells, leading to apoptosis.

## MATERIALS and METHODS

### *Cell lines*

The RM-1 mouse prostate cancer cell line was established from a ras + myc-induced primary tumor, derived in the mouse prostate reconstitution model in C57BL/6 mice (obtained from Dr. Timothy Thompson, Baylor College of Medicine, Houston, TX; Thompson *et al.*, 1989; Baley *et al.*, 1995). RM-1 is androgen insensitive, susceptible to CTL lysis, exhibits low levels of MHC class I molecule expression that are up-regulated in response to IFN- $\gamma$ , and only mildly immunogenic (Baley *et al.*, 1995; Kawakita *et al.*, 1997; Nasu *et al.*, 1999). Cells were grown in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS), 10 mM HEPES, penicillin (100 U/ml), and streptomycin (100 mg/ml), passaged by trypsinization and maintained with routine media changes. YAC-1 is a NK-sensitive mouse lymphoma cell line (ATCC, MD), maintained in RPMI-1640 with 10% FBS. Materials for cell culture were obtained from Sigma Chemical Company (St. Louis, and MO).

### *Adenoviral vectors*

A replication-incompetent, E1-deleted adenovirus expressing mouse IL-12 was constructed as previously described (Caruso *et al.*, 1996). The p40 and p35 mIL-12 subunits, connected by an internal ribosomal entry site, were placed under the control of the Rous sarcoma virus (RSV) promoter. To construct a replication incompetent adenovirus expressing soluble Fas (sFas) immunoglobulin (Ig), the extracellular domain of Fas was amplified by PCR and ligated to the Fc region of mouse IgG<sub>2a</sub>. The sFas-Ig cDNA was placed in the adenovirus backbone driven by the RSV promoter. The pAd.RSV-sFasIg was co-transfected with pBHG10 in 293 cells by the calcium phosphate precipitation method to yield Ad.sFasIg. Preliminary characterization noted the presence of both Fas and mouse IgG in MCA-26 cells (mouse colon cancer cells) transfected with Ad.sFasIg by fluorescence-activated cell sorting (FACS) anal-

ysis (anti-FasIgG and anti-mouseIgG, Pharmingen). DL-312, an E1 region-deleted Ad without transgene, was used a vector control. Large-scale production of vector was achieved following expansion in 293 cells and double cesium gradient ultracentrifugation purification. The viral titer was ascertained in 293 cells in a plaque assay and expressed as plaque-forming units (PFU) per milliliter.

### *In vivo gene therapy*

Orthotopic tumors were induced as previously described (Hall *et al.*, 1997). Briefly, tumors were induced by an injection of 7500 RM-1 cells into the dorsolateral prostates of C57/BL6 mice (Jackson Laboratories) or NKT knockout mice (C57/BL6 background V $\alpha$  14 NKT knockouts, obtained from Dr. Masaru Taniguchi, Chiba, Japan) (Cui *et al.*, 1997). Vector injections were performed on the 6th day post-inoculation when tumors essentially filled the lobe injected. To evaluate the induction of systemic antitumor activity against pre-established metastasis, a synchronous metastatic model was used, as previously described (Hall *et al.*, 1998). Briefly, lung tumors were induced by a tail vein injection of RM-1 cells on the same day as primary tumor induction, leaving sufficient time for establishment of microscopic lesions prior to vector injection of the primary prostate tumor (day 6). At sacrifice the lungs were removed and placed in Bouin's solution for several hours prior to transfer into 70% ethanol. Lung metastases were then quantified by counting visible lesions with a dissecting microscope. All animals were used in accordance with established protocols approved by the institutional animal use committee.

### *Immunohistochemistry*

Tissues from both primary prostate tumors and lung were either formalin fixed (10%), followed by paraffin embedding for sectioning or snap frozen in O.C.T. compound (Tissue-Tek, Sakura Finetek, Torrance CA) for frozen sectioning. After sectioning, formalin-fixed tissues were stained with hematoxylin and eosin for routine histopathologic screening. Presence of apoptotic activity was achieved by TUNEL assay as per manufacturer instructions (Apop Tag, Oncor, Gaithersburg, MD). The number of positive bodies were counted at 400 $\times$  by viewing across the long and short axis of tissue sections and expressed as number of bodies per high-power field (HPF). Immunohistochemistry to determine expression or presence of Fas (hamster anti-mouse IgG; Pharmingen, San Diego, CA) and FasL (goat anti-rat IgG; Santa Cruz Biotechnologies, CA) was performed on frozen tissue sections.

### *Inhibition of apoptosis in vivo*

Inhibition of apoptosis was achieved using the general caspase inhibitor, Z-Val-Ala-Asp (Ome)-fluoromethyl ketone (z-VAD-FMK, Enzyme Systems Products, Livermore, CA). *In vitro* z-VAD-FMK was added to plated cells at a dose of 20  $\mu$ M at the time of IFN- $\gamma$  or phosphate-buffered saline (PBS) exposure. Viable cells as per trypan blue exclusion were counted 24 hr later. *In vivo* z-VAD-FMK was administered to mice in twice daily i.p. injections of 200  $\mu$ g, beginning the day of virus injection through the 8 days prior to sacrifice, as previously reported (Hotchkiss *et al.*, 1999; Piguet *et al.*, 1999).

### *In vivo cytotoxic assays*

TIL were extracted for *in vitro* analysis as previously described (Hall *et al.*, 1998). At designated time points, excised primary tumors from treatment and control groups were pooled and mechanically lysed between glass sides in Hanks' balanced salt solution (HBSS) with 1% fetal calf serum (FCS). Tumor debris was removed by serial gravity precipitations. The resulting single-cell suspension was then treated with red cell lysis buffer (Sigma Chemical Co.) and, following precipitation, passed through cotton wool pipettes. After washing and resuspension, viable lymphocytes, as determined by exclusion of trypan blue, were counted and exposed at 37°C to chromium-51 ( $^{51}$ Cr)-loaded targets (150  $\mu$ Ci/5  $\times$  10 $^6$  cells) for 4 hr at various effector-to-target ratios in triplicate. The percentage of specific lysis was calculated as (experimental release - spontaneous release)/(maximal release - spontaneous release) from gamma counter measurements of supernatant harvested by the Skatron system (Skatron Instruments Inc, VA). Mechanically lysed splenocytes were purified by double-density centrifugation (Lympholyte-M solution, Cedarlane Labs, CA) and prepared for cytotoxic T lymphocyte (CTL) assay by priming with low-dose mIL-2 (20 U/ml, Pharmingen, San Diego, CA) in the presence of lethally irradiated RM-1 cells for 5 days. Primed splenocytes were then collected, counted, and exposed for 4 hr at varying effector to target ratios with the measurement of radioactivity as detailed above.

### *Antibody-mediated in vivo lymphocyte depletions*

Specific lymphocyte populations were depleted *in vivo* through i.p. injections of the appropriate antibodies beginning 1 day prior to Ad.mIL-12 injection, as previously described (Hall *et al.*, 1998). Inactivation of CD4/CD8 T cells was accomplished with purified ascites from hybridoma GK 1.5 (anti-CD4 T-cells) (ATCC, Rockville, MD) and from hybridoma 2.43 (anti-CD8 T cells) (ATCC, Rockville, MD). NKs were inactivated with anti-asialo GM1 IgG (Wako Chemicals, Reston, Va), and controls with rabbit IgG (Dako Corp, Carpinteria, Ca) and rat IgG (Accurate Chemical & Scientific Corp, Westbury, NY). GR-1 leukocytes were depleted with anti-Ly-6 IgG (Pharmingen, San Diego, Ca) (Cavallo *et al.*, 1999; Mendritta *et al.*, 1999). Anti-NK and control antibody injections were given every other day, whereas anti-CD4, anti-CD8, and Anti-Ly-6 IgGs were given every third day as determined previously. In each case, the end point was loss of >90% of each subset from spleens of treated tumor naive mice.

### *Measurement of serum cytokines*

Blood was drawn from animals at designated time points via tail vein. After coagulation at room temperature serum from each group was pooled and frozen at -70°C. Serum cytokine determination was achieved with commercially available enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, Minneapolis, MN).

### *In vitro actions of IL-12 and IFN- $\gamma$ on RM-1 cells*

The potential for IL-12 or IFN- $\gamma$  to mediate toxicity *in vitro* was assayed by adding recombinant mIL-12 (2–200 ng/ml, Biosource International) or mIFN- $\gamma$  (50–200 U/ml, Pharmingen) to media of plated RM-1 cells. Cells were harvested 48 hr

later and viable cells, as determined by trypan blue exclusion (0.4%, Sigma Chemical Company, St. Louis, MO), were counted. The ability of IFN- $\gamma$  to impact of Fas and/or FasL was addressed through FACS analysis of stained cells. RM-1 cells *in vitro* were randomized to exposure to 100 U/ml of mIFN- $\gamma$  or PBS for 24 hr. Cells were harvested, fixed in 0.1% paraformaldehyde, and stained with fluorescein isothiocyanate (FITC)-labeled anti-Fas IgG (hamster anti-mouse Fas IgG, Pharmingen), FITC-labeled anti-FasL (hamster antimouse FasL IgG, Pharmingen) or FITC-labeled hamster IgG. Cells were processed through FACS scan to ascertain the percentage and intensity of Fas/FasL staining. Mediation of the growth inhibitory activity of IFN- $\gamma$  through the Fas/FasL pathway in RM-1 cells was addressed through *in vitro* growth assays. RM-1 cells were exposed to PBS or escalating doses of IFN- $\gamma$  for 24 hr. Each treatment group had been randomized to receive 10  $\mu$ g/ml anti-FasL IgG (Pharmingen) or hamster anti-mouse IgG (Pharmingen). In parallel studies, blockage of Fas/FasL was achieved by using conditioned media from RM-1 cells transfected with Ad.sFasIg at a MOI of 50 (transduction of 50% of cells) for 48 hr. This media was added at the time of PBS or IFN- $\gamma$  exposure. Likewise, blockage of apoptosis was achieved by adding z-VAD-FMK (20  $\mu$ M) at the time of PBS or IFN- $\gamma$ . Viable cells were counted 24 hr later.

#### *Blockage of Fas/FasL pathway in vivo*

To block Fas/FasL interactions *in vivo* tumor-bearing mice were injected with DL312 or Ad.sFasIg twice. Mice were randomized to  $1 \times 10^8$  PFU to either vector by tail vein 2 days prior to vector injection of the primary tumor (day 4 post-tumor cell inoculation), followed by a second injection at a dose of  $1 \times 10^9$  PFU directly into the primary tumor with/without Ad.IL-12. Mice were sacrificed on day 14 for evaluation of primary tumor wet weight and the number of lung metastases.

## RESULTS

#### *In vivo gene therapy*

To determine the *in vivo* therapeutic dose of Ad.mIL-12, a dose escalation experiment was performed in the synchronous metastasis model. Established prostate tumors were injected in half-log increments from  $5 \times 10^8$  to  $1 \times 10^{10}$  PFU of Ad.mIL-12. A total of  $1 \times 10^{10}$  PFU was the maximum dose tested given volume constraints at higher dosing that would result in gross spillage of vector into the peritoneal cavity. All animals were sacrificed at 14 days post-tumor cell inoculation, with all groups appearing healthy through the 8 days post-Ad.mIL-12 injection. By wet weight measurements, there was a dose-dependent inhibition of primary tumor growth (Fig. 1A), whereas reductions in the number of lung metastases were only encountered at higher doses of Ad.mIL-12 (Fig. 1B). A vector dose controlled study comparing the two higher doses was performed in the synchronous metastasis model. By 8 days, post-vector injection of  $5 \times 10^9$  and  $1 \times 10^{10}$  PFU Ad.mIL-12 resulted in tumors which were  $75 \pm 3\%$  and  $83 \pm 2.6\%$ , respectively, smaller than controls, but this difference only approached statistical significance ( $p = 0.053$ , *t*-test) (Fig. 1C). Although both doses inhibited lung metastases,  $32 \pm 6\%$  and  $58 \pm 5\%$  compared to


control, the higher dose was clearly superior ( $p = 0.035$ , *t*-test,  $5 \times 10^9$  PFU versus  $1 \times 10^{10}$  PFU) (Fig. 1D). Likewise, a survival study in mice bearing only primary tumors was performed with both doses of Ad.mIL-12. Again, the higher dose was superior with a mean survival of  $26.1 \pm 1.7$  days for treated mice compared to  $16.5 \pm 0.35$  days for control tumors (Fig. 1E,  $p < 0.0001$ , Mantel-Cox Log Rank test).

#### *Induction of apoptosis by Ad.mIL-12*

By the second day post-Ad.mIL-12 injection, treated primary tumors contained areas of necrosis dominated by a marked influx of polymorphic neutrophils (PMNs) but also containing lymphocytes, eosinophils, and macrophages. TUNEL assay noted the induction of apoptosis at a mean level six times higher than control tumors ( $p < 0.0001$ , *t*-test) (Fig. 2A) in two distinct patterns. The first was notable for localized sheets of apoptotic cells in close association with the necrotic areas with  $\sim 100$  apoptotic bodies per HPF (Fig. 3A–C). The second pattern was a diffuse but modest increase in apoptosis, approximately two times higher than background. By the fourth day post-vector injection the inflammatory infiltrate and accompanying sheets of apoptotic cells had resolved. The more diffuse pattern of apoptosis continued at approximately two times control (Fig. 2A) ( $p = 0.004$ , *t*-test). By the sixth day post-vector injection, no differences in apoptosis were apparent between IL-12-treated and control tumors. Histopathology of lung lesions during the 6 days post-vector injection failed to demonstrate the type or degree of inflammation seen in the primary tumor. However, TUNEL assay of lung lesions noted a doubling of apoptosis with Ad.mIL-12 therapy compared to controls ( $p = 0.0006$ , *t*-test) (Figs. 2B and 3D,E).

The functional significance of apoptosis in Ad.mIL-12-mediated growth suppression was addressed using the caspase inhibitor, z-FMK-VAD, in the synchronous metastasis model. Analysis of tumor tissue by TUNEL assay 2 days following injection with Ad.mIL-12 and receiving z-FMK-VAD noted a reduction in apoptotic activity from six times control levels to  $\sim 1.5$  times higher than control levels ( $5.17 \pm 1.17$  apoptotic bodies for Ad.mIL-12+z-FMK-VAD versus  $3.18 \pm 0.71$  for control and  $18.68 \pm 4.5$  for Ad.mIL-12). This decrease in apoptotic activity significantly reduced the ability of Ad.mIL-12 to mediate growth suppression, both within the primary tumor and the lung lesions (Fig. 4). However, the degree of influence was different within the primary and metastatic lesions. By 8 days post-vector injection primary tumors treated with Ad.mIL-12 and z-FMK-VAD were 36% larger than Ad.mIL-12-treated tumors as compared to control tumors ( $p = 0.0013$ , *t*-test) but remained significantly smaller than control tumors ( $p = 0.012$ , *t*-test). In contrast inhibition of apoptosis resulted in abrogation of IL-12-mediated growth effects on the average number of lung lesions ( $p = 0.42$ , *t*-test, control versus Ad.mIL-12+z-FMK-VAD).


Histopathology noted a relatively high proportion of PMNs within the areas of necrosis associated with apoptosis. Examination of tumors treated with z-FMK-VAD at day 2 noted the continued presence of clustered PMNs within Ad.mIL-12 treated tumors without the associated sheets of apoptotic cells, although there were scattered more localized areas of PMNs and apoptosis. To explore directly the role of these cells in the induction of apoptosis and resulting growth inhibition, IL-12



**FIG. 1.** Growth-suppressive activities of Ad.mIL-12 *in vivo*. (A and B). Dose escalation study. Established primary tumors in the synchronous metastasis model were injected with escalating doses of Ad.mIL-12 or PBS. All mice were sacrificed 8 days later and the wet weight of the primary tumor (A) and the number of lung metastases per lung recorded (B) and compared to control (buffer only). (C and D) Dose control study. Established tumors were injected with Ad.mIL-12 or control vector at  $1 \times 10^{10}$  PFU. All mice were sacrificed 8 days later for recording of primary tumor wet weight (C) or average number of lung metastases per lung (D). (E) Survival study. Mice with primary prostate tumors only were injected with Ad.mIL-12 or control vector at  $1 \times 10^{10}$  PFU. Time of death was recorded to generate a survival curve. For A–D, each bar represents the average  $\pm$  SE. (For A and B,  $n = 4$  per group; for C and D,  $n = 12$  mice per group; for E,  $n = 8$  mice per group.)

gene therapy was performed in mice depleted of GR-1<sup>+</sup> cells. By day 2 post-vector injection, histopathology noted the absence of significant necrosis in tumors from Gr-1- Ad.mIL-12 mice, whereas TUNEL assay noted only the diffuse pattern of apoptosis and a lowering of average apoptotic activity (Fig. 5A). The reduction in apoptotic activity in GR-1<sup>-</sup> tumors correlated with the abrogation of IL-12-mediated growth suppression of

primary tumors; these tumors were on average more than three times larger than Ad.mIL-12-treated tumors and approached the size of control tumors (Ad.mIL-12+isotype IgG versus Ad.mIL-12+anti-Gr-1 IgG,  $p = 0.03$ ; Control tumors versus Ad.mIL-12+anti-Gr-1 IgG,  $p = 0.1$ , *t*-test)(Fig. 5B). In contrast, no detrimental effect was noted with regard systemic growth suppression (Fig. 5C).




**FIG. 2.** Apoptosis following Ad.mIL-12. (A) Serial assay of apoptosis in primary tumors. Vector control and Ad.mIL-12-treated tumors were prepared for TUNEL assay on days 2, 4, and 6 post vector injection. The number of apoptotic cells per HPF (400 $\times$ ) were counted across the long and short axis of each tissue section and reported as the average number of apoptotic cells per HPF  $\pm$  SD. ( $n = 9$  for each condition.) (B) Assay for apoptosis in lung lesions. Cross sections of lungs from control and Ad.mIL-12-treated animals were prepared for TUNEL assay from day 6 and handled as described above. This day was chosen to ensure adequate size of lesions for accurate counting of apoptotic bodies. ( $n = 9$  for each condition.)

#### Immunological assays

The induction of an immune response was studied first by identifying the presence of antitumor lymphocytes (TIL) harvested sequentially from treated and control primary tumors in a  $^{51}\text{Cr}$  release assay. No discernible lytic activity was noted until the eighth day post vector injection, at which time both RM-1 and YAC-1 cells were lysed by TIL from Ad.mIL-12 treated tumors, implying the induction of a NK response (Fig. 6A). The *in vivo* role of NKs in growth suppression was addressed through antibody-directed depletion of specific candidate lymphocyte populations during Ad.mIL-12 therapy in two independent experiments with distinct end points. In the first study, mice in the synchronous metastasis model were sacrificed at 8 days post-vector to study influences on primary and

systemic growth suppression in this time period. Abrogation of NK activity had no effect on either local or systemic growth suppression. However, negation of CD4 and CD8 T cells reduced IL-12 effects, because resulting primary tumors were  $\sim 20\%$  larger than those treated with IL-12 in intact animals ( $p = 0.0014$ , versus Ad.mIL-12 + control IgG,  $t$ -test), but there was no influence on the number of lung metastases (Fig. 6B,C).

In the second series of experiments, the longer-term role of an immune response was addressed in a survival study. Loss of NK cells had a profound detrimental effect on Ad.mIL-12-mediated survival, lowering mean survival from  $24 \pm 1.2$  days to  $18 \pm .4$  days, although remaining an improvement over control animals,  $18 \pm 0.4$  days versus  $16 \pm 0.3$  days ( $p = 0.012$ , Mantel-Cox Log Rank) (Fig. 6D). Likewise, loss of T cells had a negative effect but not to the degree of NK loss,  $21.2 \pm .2$  days




**FIG. 3.** TUNEL assay following Ad.mIL-12 therapy. (A–C) Photomicrographs of primary tumors harvested 2 days post vector injection. (A) Localized areas of apoptosis marked by arrows of tumor cells between normal prostate glands. These areas correlate to necrosis with high numbers of PMNs by H&E. (100 $\times$ ). (B) High-power view (400 $\times$ ) of a representative area of apoptosis. (C) Matched control tumor noting absence of localized areas of apoptosis in background of diffuse apoptotic activity (100 $\times$ ). (D and E) Photomicrograph of lung lesions from Ad.mIL-12-treated (D) and control (E) mice sacrificed day 6 post-vector, noting difference in numbers of positive cells. (Original magnification, 100 $\times$ .)

versus  $24.2 \pm 1.2$  days ( $p = 0.03$ , Mantel-Cox Log Rank). No CTL activity could be demonstrated within splenocytes from the same animals 10 days post-vector injection (data not shown). Because NKT cells have been identified as an important mediator of IL-12-mediated growth suppressive activities (Cui *et al.*, 1997), a survival study with Ad.mIL-12 gene therapy was performed in NKT knockout mice to subcategorize NK activity. Mean survival for IL-12-treated NKT mice was  $26.8 \pm 3.8$  days versus  $25.4 \pm 2.3$  days for IL-12-treated wild-type


mice in a parallel experiment ( $p = 0.33$ , Mantel-Cox Log Rank).

#### *Role of IFN- $\gamma$ and the Fas/FasL pathway*

Studies thus far have noted that both GR-1-mediated apoptosis and an immune response are important in controlling growth of the injected primary tumor, but have not elucidated the basis for antimetastatic activity. The role for IL-12-induced



**FIG. 4.** Effect of apoptosis inhibition on Ad.mIL-12-mediated growth suppression. To ascertain the functional significance of apoptosis, the general caspase inhibitor, z-VAD-FMK (200  $\mu$ g), was injected i.p. twice a day beginning on the day of vector injection (control vector or Ad.mIL-12). All mice were sacrificed on the eighth day post-vector injection for assay of primary tumor wet weight (A) and average number of lung metastases per lung (B). Each bar represents the average  $\pm$  SD. ( $n = 5$  for each group.)




**FIG. 5.** Effect of GR-1 leukocyte depletion on Ad.mIL-12 therapy. (A) Differences in average number of apoptotic bodies per HPF under different treatment conditions. Tumors were harvested on day 2 post-vector injection. (B) Beginning the day prior to vector injection mice were divided to receive i.p. injections of anti-GR-1 antibody or control antibody every third day until all animals were sacrificed on the eighth day post-vector injection. Assay of efficacy was determined through primary tumor wet weight and average number of lung metastases per lung. Each bar represents the average  $\pm$  SD. ( $n = 5$  for each group.)

IFN- $\gamma$  expression in directing antimetastatic effect was addressed. ELISA measurement of serum noted 2 peaks IL-12, the first at day 2 and the second on day 8 post-vector injection (Fig. 7A). Likewise, 2 peaks of IFN- $\gamma$  were detected on day 4 and day 11 post-vector injection (Fig. 7B). Measurements of serum levels of IFN- $\gamma$  on the eighth day post-vector inject in intact mice versus CD4/CD8 T cell- and NK-depleted mice demonstrated an average 35% reduction in T cell-depleted mice ( $p = 0.0097$ , compared to Ad.mIL-12 + control IgG,  $t$ -test), whereas an average 15% reduction was noted in NK-depleted mice, although this was not statistically significant ( $p = 0.64$ , compared to Ad.mIL-12 + control IgG,  $t$ -test). The potential cytotoxicity of either IL-12 or IFN- $\gamma$  was tested by adding recombinant cytokines to RM-1 cells *in vitro*. Doses of IL-12 up to 100x greater than that measured *in vivo* (200 ng/ml) had no growth-suppressive effect on RM-1 cells (data not shown). However, exposure to IFN- $\gamma$  (200 U/ml; 1000x lower than IFN- $\gamma$  measured in serum of treated mice) resulted in a 40% reduction in the number of RM-1 cells (Fig. 8A). Fas is a transmembrane receptor within the tumor necrosis factor (TNF) superfamily, which initiates apoptosis when activated by its ligand, FasL, with further sensitization following IFN- $\gamma$  exposure (Weller *et al.*, 1994). Therefore, the role of host produc-

tion of IFN- $\gamma$  in response to Ad.mIL-12 and its ability to mediate apoptosis through the Fas/FasL pathway was addressed. *In vitro* a 24-hr exposure to IFN- $\gamma$  resulted in an increase in cell-surface expression of Fas from 15–20% to 40–55% (Fig. 8B), whereas expression of FasL changed only slightly (10% to 20–25%). Blocking FasL with an antiFasL IgG blunted the IFN- $\gamma$  dose-dependent killing of RM-1 (Fig. 8A). In addition, co-exposure of RM-1 to IFN- $\gamma$  in the presence of Ad.sFasIg-conditioned media or z-VAD-FMK negated the inhibitory effects of cytokine treatment (data not shown).

*In vivo* immunohistochemistry noted a change in the pattern of Fas staining as early as 2 days following Ad.mIL-12 injection compared to control tumors (Fig. 9), whereas staining for FasL was limited to occasional infiltrating lymphocytes in IL-12 treated tumors. Ad.sFasIg was utilized to block Fas/FasL interactions *in vivo*. Use of Ad.sFasIg in animals treated with Ad.mIL-12 resulted in a limited negative impact on growth suppression within the primary tumor with lesions being ~10% larger than Ad.mIL-12 alone as compared to control ( $p = 0.046$ ,  $t$ -test) (Fig. 8C). However, Ad.mIL-12-directed systemic growth suppression was completely negated with the addition of Ad.sFasIg, indicating the role of Fas/FasL interactions underlying the inhibition of lung metastasis development.




**FIG. 6.** Immune response post-Ad.mIL-12 therapy. (A) Time course induction of TIL in a  $^{51}\text{Cr}$  release assay. Fresh TIL were harvested days 2, 4, 6, and 8 from control and Ad.mIL-12-treated primary tumors and exposed *in vitro* to  $^{51}\text{Cr}$ -loaded RM-1 and Yac-1 cells. Each bar represents the E:T ratio of 100:1 and is the average of triplicate wells. (B and C) Effect of T- and NK-cell depletion on Ad.mIL-12-mediated growth suppression. Mice in the synchronous metastasis model were randomized to receive i.p. injections beginning the day before vector injection and continuing as outlined in Materials and Methods for 8 days post injection. All mice were sacrificed at day 8 post-vector injection for analysis of primary tumor wet weight (B) and the average number of lung metastases per lung (C)  $\pm$  SD on each case. ( $n = 8$  for each group.) (D) Effect of lymphocyte depletion of survival. Detrimental effects of lymphocyte depletion on longer-term growth suppression was determined in mice with primary tumors only randomized to receive the appropriate antibodies as in A and B, but continued for the duration of a survival experiment. ( $n = 5$  in each group.)

## DISCUSSION

Use of Ad.mIL-12 gene therapy in the RM-1 tumor model results in growth suppression both within the transduced tumor and in pre-established tumor lesions remote from IL-12-ex-

pressing tissues in a dose-dependent manner, which translates into enhanced survival. Analysis of serum noted 2 peaks of both IL-12 and IFN- $\gamma$ . Analysis of the underlying basis for these activities in the primary notes two phases of growth suppression as manifest by apoptosis within the first 2 days post-IL-12 ther-




**FIG. 7.** ELISA serum measurements of IL-12 and IFN- $\gamma$ . Serum from tumor-bearing mice treated with Ad.mIL-12 or control vector was assayed for IL-12 (A) and IFN- $\gamma$  (B) by ELISA. Each data point represents the average of pooled blood samples for each group on each day.

apy followed by an induction of an immune response after 8 days post-vector injection. Apoptosis has been noted in two prior reports as a potential mediator of growth suppression following local IL-12 gene expression (Dias *et al.*, 1998; Wang *et al.*, 1999), in one case as early as 24 hr (Dias *et al.*, 1998). However, the mechanism underlying this activity was not explored. In the present study serial assay of primary tumors noted the presence of apoptosis within 48 hr of vector injection which had dissipated by the sixth day in two distinct patterns. The dominant pattern demonstrated localized but high levels of apoptosis in close proximity to an associated inflammatory infiltrate containing a high percentage of PMNs and eosinophils. The second pattern of apoptotic activity was diffuse and responsible for a more modest increase in cell death. Inhibition of the lung lesions was associated with the diffuse pattern of apoptosis without an inflammatory infiltrate. Use of the general caspase inhibitor, z-VAD-FMK, demonstrated the functional importance of apoptosis in both local and remote growth suppression induced by Ad.mIL-12 therapy.

Although roles in tumor regression have focused on T cell, NKs, and NKTs as major cellular effectors of IL-12-mediated growth suppression, mostly descriptive roles for PMNs have thus far been determined. Indeed, each of these cell types may be recruited into IL-12-expressing benign or malignant tissues (Allavena *et al.*, 1994; Tsung *et al.*, 1997; Bussolati *et al.*, 1998; Ha *et al.*, 1998; Papp *et al.*, 2000). In IL-12-treated SCID mice depleted of NKs, PMNs and macrophages surrounding regressing tumor nodules were thought to mediate growth suppression (Siders *et al.*, 1998). More direct evidence has noted that depletion of PMNs prior to IL-12 therapy has a negative impact on ef-

ficacy, but the mechanism through which these activities were mediated was not pursued further (Cavallo *et al.*, 1999; Mendiatta *et al.*, 1999). In the present study, PMNs and, to a lesser extent, eosinophils were localized to sites of profoundly high levels of apoptosis. Depletion of GR-1<sup>+</sup> cells resulted in a loss of apoptotic activity which correlated to a significant negative impact of local growth suppression to a point where on average IL-12-treated tumors were not statistically different in size than control tumors. Therefore, one would postulate that the PMNs are recruited to the area by locally high levels of IL-12 leading to concentrated but very high levels of apoptosis. Because PMNs were present in tumors treated with z-FMK-VAD, with some higher density in some breakthrough areas of apoptosis, it would appear that the PMNs are not present as a result of apoptosis but are directing it. The ability of PMNs to destroy tumor tissue such as following FasL transduction has been documented in the literature, but it is unclear through what mechanism this occurs and whether this is tumor specific or involves random tissue destruction in an area of stimulation (Arai *et al.*, 1997; Seino *et al.*, 1997). Certainly, the present study demonstrates that PMN-mediated killing may be directed through induction of apoptosis, which is a rapid and powerful response; however, it is localized, as evidenced by the lack of impact on lung metastases. However, rapid and intense apoptosis leading to areas of necrosis may set the stage to provide tumor antigen necessary to induce an immune response.

The role of eosinophils in the observed tumor killing is more uncertain. Eosinophils have been noted to mediate antitumor activity following IL-4 therapy (Tepper *et al.*, 1992), although others have reported that PMNs are actually responsible for this




**FIG. 8.** Fas/FasL Interactions. (A) *In vitro* IFN- $\gamma$  toxicity. Plated RM-1 cells were exposed to escalating doses of IFN- $\gamma$  with or without anti-FasL antibody. Twenty-four hours later, viable cells as assessed by trypan blue exclusion were counted. Each bar represents the average of triplicate wells  $\pm$  SD. (B) FACS analysis of Fas expression following IFN- $\gamma$  exposure. Plated RM-1 cells were exposed to IFN- $\gamma$  or PBS. Twenty-four hours later, cells were prepared for staining with anti-Fas or control antibodies and FACS analysis. (C) *In vivo* effects of blocking Fas/FasL. Tumor-bearing mice were randomized to receive tail vein injections of control vector or Ad.sFasIg 2 days prior to tumor vector injection at which time primary tumors were injected with control vector or Ad.mIL-12  $\pm$  Ad.sFasIg or DL312. All mice were sacrificed 8 days post-vector injection with assay of efficacy determined through average primary tumor wet weight and average number of lung metastases per lung  $\pm$  SD. ( $n = 7$  for each group.)

growth suppression (Noffz *et al.*, 1998). But studies focusing on asthma and responses to parasitic infection have noted the ability of IL-12 to inhibit eosinophilia (Gavett *et al.*, 1995; Mehlotta *et al.*, 1998; Schwarze *et al.*, 1998). Therefore, it is unclear if eosinophils are present but are functionally inactive,

or in the case of malignancy IL-12 acts differently on eosinophils to mediate growth suppression. Further studies will be necessary to understand reasons for eosinophil recruitment and address a potential role of eosinophils in IL-12 therapy.

It is clear that the induction of apoptosis is an important as-



**FIG. 9.** Fas immunohistochemistry. Frozen sections of tumor tissue harvested day 2 post-vector injection and stained for either Fas. Distinct staining pattern for Fas is noted in Ad.mIL-12 treated tissue (A) compared to control (B), as evidenced by more distinctive "haloing" of cellular membrane. (Original magnification, 400 $\times$ .)

pect of Ad.mIL-12 therapy; however, the presence of prolonged survival enhancement in this aggressive model of prostate cancer appeared not to be solely related to this mode of killing. NK activity was noted within TIL by 8 days post-Ad.IL-12 therapy, depletion of which within the same time period had little effect on either local or systemic growth suppression, but in the long term exhibited marked importance in mediating enhanced survival through growth suppression of the primary tumor. This would indicate that the NK response is most active in the time period following the eighth day post-vector injection. T cells too were important in the activities of Ad.IL-12 therapy, but not to the degree that NKs were. Although no CTL activity could be detected within splenocytes, depletion of T cells resulted in a significant but modest negative impact on both primary tumor wet weight within the 8-day period post-vector injection and survival. This finding may reflect direct T cell killing of tumor cells, which may be more efficient due to up-regulation of Fas by IFN- $\gamma$  on target tumor cells. Furthermore, the second peak of IL-12 and IFN- $\gamma$  would indicate the induction of an immune response. However, the significant reduction in IFN- $\gamma$  levels within the second peak in the absence of T cells may be negatively influencing secondary consequences of IFN- $\gamma$ , such as reductions in NK activity or in FasL/Fas interactions. Indeed, both local and systemic effects of Ad.mIL-12 in this model were dose dependent, with significant differences documented from doses differing by 50%. Therefore, a 35% reduction in IFN- $\gamma$  in mice depleted of T cells itself may be responsible for reductions in efficacy in this scenario. Interpretations of the functional significance of changes in outcome of IL-12 therapy performed in antibody-depleted or nude mice may not denote only direct responsibility but may also be related to the secondary functions of IFN- $\gamma$ .

Both GR-1-mediated apoptosis and the NK/T cell immune response played a critical role in controlling local tumor growth, but neither had any role in the inhibition of lung metastases. Use of z-VAD-FMK had implicated apoptosis as important in mediating the anti-metastatic activity with the TUNEL assay documenting a diffuse pattern of apoptosis approximately two

times above background in the lung lesions, similar to that noted in the primary tumor interspersed between necrotic areas. The exploration of the Fas/FasL pathway as the basis for inducing apoptosis centered on several lines of evidence. RM-1 cells constitutively express low levels of both Fas and FasL; *in vitro* exposure to IFN- $\gamma$  results in increased surface expression of both surface markers, Fas > FasL. Indeed, *in vitro* growth suppression mediated by IFN- $\gamma$  at doses 1000x lower than that measured in serum of treated mice could be blunted by blockade of FasL, indicating the ability of IFN- $\gamma$  to mediate tumor cell fratricide. The use of z-VAD-FMK indicated that apoptosis was the method of death. *In vivo* interruption of this pathway with Ad.sFas-Ig had a limited influence on growth suppression within the primary tumor but resulted in a near loss of systemic antitumor activity against the established lung lesions. The difference in the degree of inhibition between the two sites is most likely related to the lack of FasL in the prostate and the presence of FasL in lung tissue. Indeed, immunohistochemistry failed to demonstrate the presence of intrinsic FasL within the prostate, confirming published observations (Sasaki *et al.*, 1998). Conversely, intrinsic FasL<sup>+</sup> lung cells which will trans-activate Fas<sup>+</sup> tumor cells has been reported as a mechanism for decreased melanoma metastases for Fas<sup>+</sup> tumor cells versus Fas<sup>-</sup> tumor cells (Owen-Schaub *et al.*, 1998) to add additional negative pressure on Fas<sup>+</sup> tumor cells in the metastatic lesions. In the present study baseline apoptosis in control lung lesions was double that of control orthotopic prostate tumors, perhaps indicative of this phenomenon against even baseline Fas expression of RM-1 cells. A potential further source of FasL would be host T cells and NKs; yet depletion of these subsets had no detrimental effect on antimetastatic activity. A secondary point lies in the obvious differential in tumor sizes at the time of therapy (macroscopic versus microscopic), which may be further supported through the loss of systemic activity following Ad.mIL-12 therapy, with higher metastatic tumor burdens achieved by injecting more RM-1 cells via the tail vein to overwhelm this process (unpublished observation).

In conclusion in this synchronous metastatic model of

prostate cancer growth control of the injected primary tumor is mediated primarily by GR-1<sup>+</sup> lymphocyte-directed apoptosis and an NK response with lesser roles for T cells and Fas/FasL interactions, whereas anti-metastatic activity is mediated by apoptosis secondary to Fas/FasL interactions.

### ACKNOWLEDGMENTS

This work was funded in part by the Edwin Beer Award from the New York Academy of Medicine and Department of Defense grant PC 99-1108.

### REFERENCES

- ALLAVENA, P., PAGANIN, C., ZHOU, D., BIANCHI, G., SOZZANI, S., and MANTOVANI, A. (1994). Interleukin-12 is chemotactic for natural killer cells and stimulates their interaction with vascular endothelium. *Blood* **84**, 2261-2268.
- ARAI, H., GORDON, D., NABEL, E.G., and NABEL, G.J. (1997). Gene transfer of Fas ligand induces tumor regression in vivo. *Proc. Natl. Acad. Sci. USA* **94**, 13862-13867.
- BALEY, P.A., YOSHIDA, K., QIAN, W., SEHGAL, I., and THOMPSON, T.C. (1995). Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer. *J. Ster. Biochem. Mol. Biol.* **52**, 403-413.
- BRAMSON, J.L., HITT, M., ADDISON, C.L., MULLER, W.J., GAULDIE, J., and GRAHAM, F.L. (1996). Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. *Hum. Gene Ther.* **7**, 1995-2002.
- BRUNDA, M.J., LUISTRO, L., WARRIOR, R.R., WRIGHT, R.B., HUBBARD, B.R., MURPHY, M., WOLF, S.F. and GATELY, M.K. (1993). Antitumor and antimetastatic activity of interleukin 12 against murine tumors. *J. Exp. Med.* **178**, 1223-1230.
- BUSSOLATI, B., MARIANO, F., CIGNETTI, A., GUARINI, A., CAMBI, V., FOA, R., PICCOLI, G., and CAMUSSI, G. (1998). Platelet-activating factor synthesized by IL-12-stimulated polymorphonuclear neutrophils and NK cells mediates chemotaxis. *J. Immunol.* **161**: 1493-1500.
- CARUSO, M., PHAM-NGUYEN, K., KWONG, Y.L., XU, B., KO-SAI, K.I., FINEGOLD, M., WOO, S.L.C., and CHEN, S.H. (1996). Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. *Proc. Natl. Acad. Sci. USA* **93**, 11302-11306.
- CATALONA, W.J., RAMOS, C.G., and CARVALHAL, G.F. (1999). Contemporary results of anatomic radical prostatectomy. *CA Cancer J. Clin.* **49**, 282-296.
- CAVALLO, F., DI CARLO, E., BUTERA, M., VERRUA, R., COLOMBO, M.P., MUSIANI, P., and FORNI, G. (1999). Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12. *Cancer Res.* **59**, 414-421.
- COLOMBO, M.P., VAGLIANI, M., SPREAFICO, F., PARENZA, M., CHIODONI, C., MELANI, C., and STOPPACCIARO, A. (1996). Amount of Interleukin-12 Available at the Tumor Site is Critical for Tumor Regression. *Cancer Res.* **56**, 2531-2534.
- COUGHLIN, C.M., SALHANY, K.E., WYSOCKA, M., ARUGA, E., KURZAWA, H., CHANG, A.E., HUNTER, C.A., FOX, J.C., TRINCHERI, G., and LEE, W.M.F. (1998). IL-12 and IL-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. *J. Clin. Invest.* **101**, 1441-1452.
- CUI, J., SHIN, T., KAWANO, T., SATO, H., KONDO, E., TOURAJI, I., KANEKO, Y., KOSEKI, H., KANNO, M., and TANIGUCHI, M. (1997). Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. *Science* **278**, 1623-1626.
- DIAS, S., BOYD, R., and BALKWILL, F. (1998). IL-12 regulates VEGF and MMPs in a murine breast cancer model. *Int. J. Cancer* **78**, 361-365.
- GAVETT, S.H., O'HEARN, D.J., LI, X., HUANG, S.K., FINKELMAN, F.D., and WILLS-KARP, M. (1995). Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice. *J. Exp. Med.* **182**, 1527-1536.
- GREENLEE, R.T., MURRAY, T., BOLDEN, S., and WINGO, P.A. (2000). Cancer Statistics 2000. *CA Cancer J. Clin.* **50**, 7-33.
- HA, S.J., LEE, S.B., KIM, C.M., SHIN, H.S. and SUNG, Y.C. (1998). Rapid recruitment of macrophages in interleukin-12-mediated tumor regression. *Immunology* **95**, 156-163.
- HALL, S.J., MUTCHNIK, S.E., CHEN, S.H., WOO, S.L.C., and THOMPSON, S.L.C. (1997). Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer. *Int. J. Cancer* **70**, 183-187.
- HALL, S.J., SANFORD, M.A., ATKINSON, G., and CHEN, S.H. (1998). Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer. *Cancer Res.* **58**, 3221-3225.
- HENDRZAK, J.A., and BRUNDA, M.J. (1995). Interleukin-12: biologic activity, therapeutic utility and role in disease. *Lab. Invest.* **72**, 619-637.
- HIRSCHOWITZ, E.A., NAAMA, H.A., EVOY, D., LIEBERMAN, M.D., DALY, J., and CRYSTAL, R.G. (1999). Regional treatment of hepatic micrometastasis by adenovirus vector-mediated delivery of interleukin-2 and interleukin-12 cDNAs to the hepatic parenchyma. *Cancer Gene Ther.* **6**, 491-498.
- HISCOX, S., HALLETT, M.B., PUNTIS, M.C., and JIANG, W.G. (1995). Inhibition of cancer cell motility and invasion by interleukin-12. *Clin. Exp. Metastasis* **13**, 396-404.
- HOTCHKISS, R.S., TINSLEY, K.W., SWANSON, P.E., CHANG, K.C., COBB, J.P., BUCHMAN, T.G., KORSMEYER, S.J., and KARL, I.E. (1999). Prevention of lymphocyte cell death in sepsis improves survival in mice. *Proc. Natl. Acad. Sci. USA* **96**, 14541-14546.
- KAWAKITA, M., RAO, G.S., RITCHIEY, J.K., ORNSTEIN, D.K., HUDSON, M.A., TARTAGLIA, J., PAOLETTI, E., HUMPHREY, P.A., HARMON, T.J., and RATLIFF, T.L. (1997). Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth. *J. Natl. Cancer Inst.* **89**, 428-436.
- MEHLOTRA, R.K., HALL, L.R., HIGGINS, A.W., DRESHAJ, I.A., HAXHIU, M.A., KAZURA, J.W., and PEARLMAN, E. (1998). Interleukin-12 suppresses filaria-induced pulmonary eosinophilia, deposition of major basic protein and airway hyperresponsiveness. *Parasite Immunol.* **20**, 455-462.
- MENDIRATTA, S.K., QUEZADA, A., MATAR, M., WANG, J., HEBEL, H.L., LONG, S., NORDSTROM, J.L., and PERICLE, F. (1999). Intratumoral delivery of IL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity. *Gene Ther.* **6**, 833-839.
- NANNI, P., ROSSI, I., DEGIOVANNI, C., LANDUZZI, L., NICOLETTI, G., STOPPACCIARO, A., PARENZA, M., COLOMBO, M.P., and LOLLI, P.L. (1998). Interleukin 12 gene therapy of MHC-negative murine melanoma metastases. *Cancer Res.* **58**, 1225-1230.
- NASTALA, C.L., EDINGTON, H.D., MCKINNEY, T.G., TAHARA, H., NALESNIK, M.A., BRUNDA, M.J., GATELY, M.K., WOLF, S.F., SCHREIBER, R.D., STORKUS, W.J. et al. (1994). Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. *J. Immunol.* **153**, 1697-1707.
- NASU, Y., BANGMA, C.H., HULL, G.W., LEE, H.M., HU, J.,

- WANG, J., MCCURDY, M.A., SHIMURA, S., YANG, G., TIMME, T.L., and THOMPSON, T.C. (1999). Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. *Gene Ther.* **6**, 338–349.
- NOFFZ, G., QIN, Z., KOPF, M., and BLANKENSTEIN, T. (1998). Neutrophils but not eosinophils are involved in growth suppression of IL-4-secreting tumors. *J. Immunol.* **160**, 345–350.
- OWEN-SCHAUB, L.B., VAN GOLEN, K.L., HILL, L.L., and PRICE, J.E. (1998). Fas and Fas ligand interactions suppress melanoma lung metastasis. *J. Exp. Med.* **188**, 1717–1723.
- PAPP, Z., MIDDLETON, D.M., RONTVED, C.M., FOLDVARI, M., GORDON, J.R., and BACA-ESTRADA, M.E. (2000). Transtracheal administration of interleukin-12 induces neutrophil responses in the murine lung. *J. Interferon Cytokine Res.* **20**, 191–195.
- PHAM-NGUYEN, K.B., YANG, W., SAXENA, R., THUNG, S.N., WOO, S.L., and CHEN, S.H. (1999). Role of NK and T cells in IL-12-induced antitumor response against hepatic colon carcinoma. *Int. J. Cancer* **81**, 813–819.
- PIGUET, P.F., VESIN, C., DONATI, Y., and BARAZZONE, C. (1999). TNF-induced enterocyte apoptosis and detachment in mice: induction of caspases and prevention by a caspase inhibitor, ZVAD-fmk. *Lab. Invest.* **79**, 495–500.
- RAKHMILEVICH, A.L., TURNER, J., FORD, M.J., MCCABE, D., SUN, W.H., SONDEL, P.M., GROTA, K., and YANG, N.S. (1996). Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. *Proc. Natl. Acad. Sci. USA* **93**, 6291–6296.
- SASAKI, Y., AHMED, H., TAKEUCHI, T., MORIYAMA, N., and KAWABE, K. (1998). Immunohistochemical study of Fas, Fas ligand and interleukin-1 beta converting enzyme expression in human prostatic cancer. *Br. J. Urol.* **81**, 852–855.
- SCHWARZE, J., HAMELMANN, E., CIESLEWICZ, G., TOMKINSON, A., JOETHAM, A., BRADLEY, K., and GELFAND, E.W. (1998). Local treatment with IL-12 is an effective inhibitor of airway hyperresponsiveness and lung eosinophilia after airway challenge in sensitized mice. *J. Allergy Clin. Immunol.* **102**, 86–93.
- SEINO, K., KAYAGAKI, N., OKUMURA, K., and YAGITA, H. (1997). Antitumor effect of locally produced CD95 ligand. *Nature Med.* **3**, 165–170.
- SGADARI, C., ANGIOLILLO, A.L., and TOSATO, G. (1996). Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. *Blood* **87**, 3877–3882.
- SIDERS, W.M., WRIGHT, P.W., HIXON, J.A., ALVORD, W.G., BACK, T.C., WILTROUT, R.H., and FENTON, R.G. (1998). T cell- and NK cell-independent inhibition of hepatic metastases by systemic administration of an IL-12-expressing recombinant adenovirus. *J. Immunol.* **160**, 5465–5474.
- TAHARA, H., ZITVOGEL, L., STORKUS, W.J., ZEH, H.J., 3RD, MCKINNEY, T.G., SCHREIBER, R.D., GUBLER, U., ROBBINS, P.D., and LOTZE, M.T. (1995). Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. *J. Immunol.* **154**, 6466–6474.
- TAN, J., NEWTON, C.A., DJEU, J.Y., GUTSCH, D.E., CHANGE, A.E., YANG, N.-S., KLEIN, T.W., and YU, H. (1996). Injection of complementary DNA encoding interleukin-12 inhibits tumor establishment at a distant site in a murine renal carcinoma model. *Cancer Res.* **56**, 3399–3403.
- TEPPER, R.I., COFFMAN, R.L., and LEDER, P. (1992). An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. *Science* **257**, 548–551.
- THOMPSON, T.C., SOUTHGATE, J., KITCHENER, G., and LAND, H. (1989). Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted model. *Cell* **56**, 917–930.
- TSUNG, K., MEKO, J.B., PEPLINSKI, G.R., TSUNG, Y.L., and NORTON, J.A. (1997). IL-12 induces T helper 1-directed antitumor response. *J. Immunol.* **158**, 3359–3365.
- VOEST, E.E., KENYON, B.M., O'REILLY, M.S., TRUITT, G., D'AMATO, R.J., and FOLKMAN, J. (1995). Inhibition of angiogenesis in vivo by interleukin 12. *J. Natl. Cancer Inst.* **87**, 581–586.
- WANG, C., QUEVEDO, M.E., LANNUTTI, B.J., GORDON, K.B., GUO, D., SUN, W., and PALLER, A.S. (1999). In vivo gene therapy with interleukin-12 inhibits primary vascular tumor growth and induces apoptosis in a mouse model. *J. Invest. Dermatol.* **112**, 775–781.
- WELLER, M., FREI, K., GROSCURTH, P., KRAMMER, P.H., YONEKAWA, Y., and FONTANA, A. (1994). Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. *J. Clin. Invest.* **94**, 954–964..
- YU, W.G., YAMAMOTO, N., TAKENAKA, H., MU, J., TAI, X.G., ZOU, J.P., OGAWA, M., TSUTSUI, T., WIJESURIYA, R., YOSHIDA, R., HERRMANN, S., FUJIWARA, H., and HAMAOKA, T. (1996). Molecular mechanisms underlying IFN-gamma-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12. *Int. Immunol.* **8**, 855–865.
- ZEH, H.J. 3D, HURD, S., STORKUS, W.J., and LOTZE, M.T. (1993). Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer. *J. Immunother.* **14**, 155–161.

Address reprint requests to:  
**Dr. Simon J. Hall**  
*The Institute for Gene Therapy and Molecular Medicine  
Mount Sinai School of Medicine  
One Gustave Levy L. Place  
New York, N.Y. 10029*

E-mail: halls01@doc.mssm.edu

Received for publication November 28, 2000; accepted after revision June 26, 2001.